PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33773286-14	2021	Pre-incubation with canertinib, pomalidomide or ubiquitination inhibitor MLN4924 totally blocked EGFR degradation by PROTACs.	pevonedistat	73-80	epidermal growth factor receptor	Homo sapiens	97-101
33807046-4	2021	NEDD8, and the target of MLN4924 inhibition, NEDD8-activating enzyme E1 (NAE1), are highly conserved in D. discoideum (Nedd8 and Nae1, respectively).	pevonedistat	25-32	NEDD8 ubiquitin like modifier	Homo sapiens	119-124
33807046-5	2021	Treatment of D. discoideum cells with MLN4924 increased the amount of free Nedd8, suggesting that MLN4924 inhibited neddylation.	pevonedistat	38-45	NEDD8 ubiquitin like modifier	Homo sapiens	75-80
33807046-5	2021	Treatment of D. discoideum cells with MLN4924 increased the amount of free Nedd8, suggesting that MLN4924 inhibited neddylation.	pevonedistat	98-105	NEDD8 ubiquitin like modifier	Homo sapiens	75-80
33799604-11	2021	Importantly, chemical inhibition of Skp2 by MLN4924 upregulated p27 and decreased Slug expression in PC3, PC3 DR12, and LAPC4 cells.	pevonedistat	44-51	S-phase kinase associated protein 2	Homo sapiens	36-40
33799604-11	2021	Importantly, chemical inhibition of Skp2 by MLN4924 upregulated p27 and decreased Slug expression in PC3, PC3 DR12, and LAPC4 cells.	pevonedistat	44-51	dynactin subunit 6	Homo sapiens	64-67
33799604-11	2021	Importantly, chemical inhibition of Skp2 by MLN4924 upregulated p27 and decreased Slug expression in PC3, PC3 DR12, and LAPC4 cells.	pevonedistat	44-51	snail family transcriptional repressor 2	Homo sapiens	82-86
33233664-7	2020	Pevonedistat treatment caused the accumulation of CDT1 and p21 in both sensitive and resistant cell lines.	pevonedistat	0-12	chromatin licensing and DNA replication factor 1	Mus musculus	50-54
33233664-7	2020	Pevonedistat treatment caused the accumulation of CDT1 and p21 in both sensitive and resistant cell lines.	pevonedistat	0-12	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	59-62
34716866-4	2022	METHODS AND RESULTS: To explore role of neddylation, HBV-replicating HepG2.2.15.7 cells and HBV-infected HepG2-hNTCP-30 cells were treated with siNEDD8 and MLN4924, a potent and selective NEDD8-activating enzyme inhibitor.	pevonedistat	156-163	NEDD8 ubiquitin like modifier	Homo sapiens	188-193
34716866-7	2022	Symmetrically, NEDD8 knockdown by siRNA or MLN4924 treatments decreased HBV replication in HepG2.2.15.7 and HepG2-hNTCP-30 cells.	pevonedistat	43-50	NEDD8 ubiquitin like modifier	Homo sapiens	15-20
34874801-5	2022	Of 691 differentially expressed genes, NAPEPLD knockdown showed synergism with MLN4924, as determined by real-time quantitative PCR and high content screening.	pevonedistat	79-86	N-acyl phosphatidylethanolamine phospholipase D	Mus musculus	39-46
34857808-6	2021	NEDD8 and RBX1 inhibition by the small molecule inhibitor pevonedistat inhibited leukemia cell growth.	pevonedistat	58-70	NEDD8 ubiquitin like modifier	Homo sapiens	0-5
34874801-6	2022	NAPEPLD knockdown enhanced the effect of MLN4924 on inhibiting proliferation and inducing apoptosis in vitro.	pevonedistat	41-48	N-acyl phosphatidylethanolamine phospholipase D	Mus musculus	0-7
34874801-9	2022	These findings indicate that MLN4924 causes extensive genomic changes in pancreatic cancer cells, and targeting NAPEPLD may increase the efficacy of MLN4924.	pevonedistat	29-36	N-acyl phosphatidylethanolamine phospholipase D	Mus musculus	112-119
34874801-9	2022	These findings indicate that MLN4924 causes extensive genomic changes in pancreatic cancer cells, and targeting NAPEPLD may increase the efficacy of MLN4924.	pevonedistat	149-156	N-acyl phosphatidylethanolamine phospholipase D	Mus musculus	112-119
34857808-6	2021	NEDD8 and RBX1 inhibition by the small molecule inhibitor pevonedistat inhibited leukemia cell growth.	pevonedistat	58-70	ring-box 1	Homo sapiens	10-14
34101829-5	2021	Here, we modulated overall neddylation and SKP2-associated ubiquitination in HSCs by using SKP2-C25, an SKP2 inhibitor, and MLN4924 (Pevonedistat) as an inhibitor of the NEDD8 system.	pevonedistat	124-131	S-phase kinase-associated protein 2	Mus musculus	43-47
34101829-5	2021	Here, we modulated overall neddylation and SKP2-associated ubiquitination in HSCs by using SKP2-C25, an SKP2 inhibitor, and MLN4924 (Pevonedistat) as an inhibitor of the NEDD8 system.	pevonedistat	124-131	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	170-175
34101829-5	2021	Here, we modulated overall neddylation and SKP2-associated ubiquitination in HSCs by using SKP2-C25, an SKP2 inhibitor, and MLN4924 (Pevonedistat) as an inhibitor of the NEDD8 system.	pevonedistat	133-145	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	170-175
34476871-9	2021	In addition, pevonedistat coadministration with CIS showed a significant decrease in caspase-3 and a significant increase in A20, beta-catenin, and Nrf2 gene expressions.	pevonedistat	13-25	caspase 3	Mus musculus	85-94
34476871-9	2021	In addition, pevonedistat coadministration with CIS showed a significant decrease in caspase-3 and a significant increase in A20, beta-catenin, and Nrf2 gene expressions.	pevonedistat	13-25	tumor necrosis factor, alpha-induced protein 3	Mus musculus	125-128
34476871-9	2021	In addition, pevonedistat coadministration with CIS showed a significant decrease in caspase-3 and a significant increase in A20, beta-catenin, and Nrf2 gene expressions.	pevonedistat	13-25	catenin (cadherin associated protein), beta 1	Mus musculus	130-142
34476871-9	2021	In addition, pevonedistat coadministration with CIS showed a significant decrease in caspase-3 and a significant increase in A20, beta-catenin, and Nrf2 gene expressions.	pevonedistat	13-25	nuclear factor, erythroid derived 2, like 2	Mus musculus	148-152
34476871-10	2021	Also, pevonedistat decreased caspase-3 cleavage to p19 in mice treated with CIS.	pevonedistat	6-18	caspase 3	Mus musculus	29-38
34476871-10	2021	Also, pevonedistat decreased caspase-3 cleavage to p19 in mice treated with CIS.	pevonedistat	6-18	interleukin 23, alpha subunit p19	Mus musculus	51-54
34476871-11	2021	Moreover, pevonedistat decreased CIS-induced upregulation of IL-6, TNF-alpha, IL-1beta, and NF-kappaB protein expressions in renal tissue.	pevonedistat	10-22	interleukin 6	Mus musculus	61-65
34476871-11	2021	Moreover, pevonedistat decreased CIS-induced upregulation of IL-6, TNF-alpha, IL-1beta, and NF-kappaB protein expressions in renal tissue.	pevonedistat	10-22	tumor necrosis factor	Mus musculus	67-76
34476871-11	2021	Moreover, pevonedistat decreased CIS-induced upregulation of IL-6, TNF-alpha, IL-1beta, and NF-kappaB protein expressions in renal tissue.	pevonedistat	10-22	interleukin 1 alpha	Mus musculus	78-86
34343486-6	2021	The neddylation inhibitor MLN4924 decreased the degradation of KLHL2/KLHL3 under high-glucose conditions with/without insulin, and transfection with KLHL2 promoted the degradation of its substrates with-no-lysine (WNK) kinases.	pevonedistat	26-33	kelch-like 2, Mayven	Mus musculus	63-68
34459035-5	2021	Consistently, pevonedistat (also known as MLN4924), an inhibitor of neddylation, inhibits the degradation of HIF1alpha in RCC4 cells stably expressing VHL in cycloheximide chase assays.	pevonedistat	14-26	hypoxia inducible factor 1 subunit alpha	Homo sapiens	109-118
34459035-5	2021	Consistently, pevonedistat (also known as MLN4924), an inhibitor of neddylation, inhibits the degradation of HIF1alpha in RCC4 cells stably expressing VHL in cycloheximide chase assays.	pevonedistat	42-49	hypoxia inducible factor 1 subunit alpha	Homo sapiens	109-118
34459035-6	2021	However, such inhibitory effect of pevonedistat on HIF1alpha degradation was not observed in HEK293 cells, which was further found to be due to CRL2VHL -independent degradation that was active in HEK293 but not RCC4 cells.	pevonedistat	35-47	hypoxia inducible factor 1 subunit alpha	Homo sapiens	51-60
34459035-6	2021	However, such inhibitory effect of pevonedistat on HIF1alpha degradation was not observed in HEK293 cells, which was further found to be due to CRL2VHL -independent degradation that was active in HEK293 but not RCC4 cells.	pevonedistat	35-47	DAN domain BMP antagonist family member 5	Homo sapiens	144-151
34459035-7	2021	After truncating HIF1alpha to its Carboxy-terminal Oxygen-Dependent Degradation (CODD) domain, we showed that pevonedistat inhibited the degradation of CODD and increased its half-life by six-fold in HEK293 cells.	pevonedistat	110-122	hypoxia inducible factor 1 subunit alpha	Homo sapiens	17-26
34343486-6	2021	The neddylation inhibitor MLN4924 decreased the degradation of KLHL2/KLHL3 under high-glucose conditions with/without insulin, and transfection with KLHL2 promoted the degradation of its substrates with-no-lysine (WNK) kinases.	pevonedistat	26-33	kelch-like 3	Mus musculus	69-74
34482362-5	2021	We found that pharmacologic inhibition of neddylation using a small-molecule inhibitor, MLN4924/Pevonedistat, increases the expression of the NK cell-activating receptor NKG2D ligands MICA and MICB on the plasma membrane of different MM cell lines and patient-derived PCs, leading to enhanced NK cell degranulation.	pevonedistat	88-95	killer cell lectin like receptor K1	Homo sapiens	170-175
34676055-4	2021	Pevonedistat, a small molecule inhibitor of the Nedd8-activating enzyme, demonstrates pre-clinical activity in multiple tumor types.	pevonedistat	0-12	NEDD8 ubiquitin like modifier	Homo sapiens	48-53
34454165-0	2021	Cardioprotective effect of MLN4924 on ameliorating autophagic flux impairment in myocardial ischemia-reperfusion injury by Sirt1.	pevonedistat	27-34	sirtuin 1	Mus musculus	123-128
34454165-7	2021	Notably, the expression levels of Rab7 and Atg5 were markedly up-regulated in MLN4924 treated cells and mice subjected to H2O2 or MI/R, respectively, while knockdown of Sirt1 in cells and heart tissue largely blocked such effect and induced autophagosome accumulation by inhibiting its fusion with lysosomes.	pevonedistat	78-85	RAB7, member RAS oncogene family	Mus musculus	34-38
34454165-7	2021	Notably, the expression levels of Rab7 and Atg5 were markedly up-regulated in MLN4924 treated cells and mice subjected to H2O2 or MI/R, respectively, while knockdown of Sirt1 in cells and heart tissue largely blocked such effect and induced autophagosome accumulation by inhibiting its fusion with lysosomes.	pevonedistat	78-85	autophagy related 5	Mus musculus	43-47
34454165-8	2021	Transmission electron microscopic analysis, histopathological assay and TUNEL detection of the heart tissues showed that the absence of Sirt1 blocked the cardioprotective effect of MLN4924 by further exacerbating the impaired autophagic flux during MI/R injury in vivo.	pevonedistat	181-188	sirtuin 1	Mus musculus	136-141
34611480-2	2021	We and others have shown that targeting the NEDD8-activating enzyme (NAE) with an investigational inhibitor pevonedistat deregulates cell cycle and mitosis in lymphoma and leukemia.	pevonedistat	108-120	NEDD8 ubiquitin like modifier	Homo sapiens	44-49
34482362-5	2021	We found that pharmacologic inhibition of neddylation using a small-molecule inhibitor, MLN4924/Pevonedistat, increases the expression of the NK cell-activating receptor NKG2D ligands MICA and MICB on the plasma membrane of different MM cell lines and patient-derived PCs, leading to enhanced NK cell degranulation.	pevonedistat	88-95	MHC class I polypeptide-related sequence A	Homo sapiens	184-188
34482362-5	2021	We found that pharmacologic inhibition of neddylation using a small-molecule inhibitor, MLN4924/Pevonedistat, increases the expression of the NK cell-activating receptor NKG2D ligands MICA and MICB on the plasma membrane of different MM cell lines and patient-derived PCs, leading to enhanced NK cell degranulation.	pevonedistat	88-95	MHC class I polypeptide-related sequence B	Homo sapiens	193-197
34482362-5	2021	We found that pharmacologic inhibition of neddylation using a small-molecule inhibitor, MLN4924/Pevonedistat, increases the expression of the NK cell-activating receptor NKG2D ligands MICA and MICB on the plasma membrane of different MM cell lines and patient-derived PCs, leading to enhanced NK cell degranulation.	pevonedistat	96-108	killer cell lectin like receptor K1	Homo sapiens	170-175
34482362-5	2021	We found that pharmacologic inhibition of neddylation using a small-molecule inhibitor, MLN4924/Pevonedistat, increases the expression of the NK cell-activating receptor NKG2D ligands MICA and MICB on the plasma membrane of different MM cell lines and patient-derived PCs, leading to enhanced NK cell degranulation.	pevonedistat	96-108	MHC class I polypeptide-related sequence A	Homo sapiens	184-188
34482362-5	2021	We found that pharmacologic inhibition of neddylation using a small-molecule inhibitor, MLN4924/Pevonedistat, increases the expression of the NK cell-activating receptor NKG2D ligands MICA and MICB on the plasma membrane of different MM cell lines and patient-derived PCs, leading to enhanced NK cell degranulation.	pevonedistat	96-108	MHC class I polypeptide-related sequence B	Homo sapiens	193-197
34482362-7	2021	Differently, MLN4924/Pevonedistat induced accumulation of MICB on the plasma membrane with no change of its mRNA levels, indicating a post-translational regulatory mechanism.	pevonedistat	13-20	MHC class I polypeptide-related sequence B	Homo sapiens	58-62
34482362-7	2021	Differently, MLN4924/Pevonedistat induced accumulation of MICB on the plasma membrane with no change of its mRNA levels, indicating a post-translational regulatory mechanism.	pevonedistat	21-33	MHC class I polypeptide-related sequence B	Homo sapiens	58-62
34502418-6	2021	Inhibition of neddylation through pharmacological blockade using MLN4924 (Pevonedistat) or genetic deletion of NEDD8 Activating Enzyme E1 Subunit 1 (NAE1), a subunit of the E1 neddylation-activating enzyme, blocks terminal myoblast differentiation partially through repressing MYOG expression.	pevonedistat	65-72	myogenin	Homo sapiens	277-281
34502418-6	2021	Inhibition of neddylation through pharmacological blockade using MLN4924 (Pevonedistat) or genetic deletion of NEDD8 Activating Enzyme E1 Subunit 1 (NAE1), a subunit of the E1 neddylation-activating enzyme, blocks terminal myoblast differentiation partially through repressing MYOG expression.	pevonedistat	74-86	myogenin	Homo sapiens	277-281
34324733-5	2021	Notably, inhibition of neddylation with MLN4924 suppressed both ubiquitination and degradation of antithrombin, which is recapitulated by silencing of the neddylation enzymes, NAE1, UBA3, and UBE2M, with small interfering RNA (siRNA).	pevonedistat	40-47	serpin family C member 1	Homo sapiens	98-110
34359705-3	2021	We previously found that the NEDD8-activating enzyme inhibitor pevonedistat induced tumor stabilization in preclinical models of poorly differentiated, clinically aggressive CRC resistant to available therapies.	pevonedistat	63-75	NEDD8 ubiquitin like modifier	Homo sapiens	29-34
34359705-5	2021	Multiple screening hits were found to be involved in the EGFR signaling pathway, suggesting that, rather than inhibition of a specific gene, interference with the EGFR pathway at any level could be effectively leveraged for combination therapies based on pevonedistat.	pevonedistat	255-267	epidermal growth factor receptor	Homo sapiens	57-61
34359705-5	2021	Multiple screening hits were found to be involved in the EGFR signaling pathway, suggesting that, rather than inhibition of a specific gene, interference with the EGFR pathway at any level could be effectively leveraged for combination therapies based on pevonedistat.	pevonedistat	255-267	epidermal growth factor receptor	Homo sapiens	163-167
34360560-6	2021	To downregulate p62, siRNA was administered, and the E3 ligases were inhibited by Heclin or MLN4924 treatment under the condition that cellular inflammatory processes were stimulated by oxLDL simultaneously initiated autophagy.	pevonedistat	92-99	sequestosome 1	Homo sapiens	16-19
35510863-6	2022	In support of this finding, overexpression of NEDD8 significantly inhibited the replication of wild-type EV71 and EGFP-EV71, but not EGFP-EV71-VP2 K69R, whereas pharmacologic inhibition of neddylation with the NEDD8-activating enzyme inhibitor MLN4924 promoted the replication of EV71 in biologically relevant cell types.	pevonedistat	244-251	NEDD8 ubiquitin like modifier	Homo sapiens	46-51
34247597-0	2021	The potential oncogenic and MLN4924-resistant effects of CSN5 on cervical cancer cells.	pevonedistat	28-35	COP9 signalosome subunit 5	Homo sapiens	57-61
34247597-12	2021	Importantly, CSN5 overexpression confers resistance to the anti-cancer effects of MLN4924 (pevonedistat) in cervical cancer cells.	pevonedistat	82-89	COP9 signalosome subunit 5	Homo sapiens	13-17
34247597-12	2021	Importantly, CSN5 overexpression confers resistance to the anti-cancer effects of MLN4924 (pevonedistat) in cervical cancer cells.	pevonedistat	91-103	COP9 signalosome subunit 5	Homo sapiens	13-17
34247597-13	2021	CONCLUSIONS: Our findings demonstrated that CSN5 functions as an oncogene in cervical cancers and may serve as a potential indicator for predicting the effects of MLN4924 treatment in the future.	pevonedistat	163-170	COP9 signalosome subunit 5	Homo sapiens	44-48
34207315-0	2021	The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma.	pevonedistat	47-59	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	31-36
34207315-7	2021	The mechanism of pevonedistat cytotoxicity depended on p53 status.	pevonedistat	17-29	tumor protein p53	Homo sapiens	55-58
34207315-11	2021	The mechanism of action of pevonedistat in neuroblastoma cell lines in vitro appears p53 dependent.	pevonedistat	27-39	transformation related protein 53, pseudogene	Mus musculus	85-88
34207315-13	2021	Novel chemotherapy agents, such as the NEDD8-activating enzyme (NAE) inhibitor pevonedistat, deserve further study in the treatment of neuroblastoma.	pevonedistat	79-91	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	39-44
34220539-8	2021	Inhibition of the NEDDylation pathway with MLN4924, an inhibitor of NEDD8-activating enzyme 1 (NAE1), significantly increased HDAC6 activity in HAECs.	pevonedistat	43-50	NEDD8 activating enzyme E1 subunit 1	Mus musculus	68-93
34220539-8	2021	Inhibition of the NEDDylation pathway with MLN4924, an inhibitor of NEDD8-activating enzyme 1 (NAE1), significantly increased HDAC6 activity in HAECs.	pevonedistat	43-50	NEDD8 activating enzyme E1 subunit 1	Mus musculus	95-99
34220539-8	2021	Inhibition of the NEDDylation pathway with MLN4924, an inhibitor of NEDD8-activating enzyme 1 (NAE1), significantly increased HDAC6 activity in HAECs.	pevonedistat	43-50	histone deacetylase 6	Mus musculus	126-131
34220539-10	2021	Further, HAECs exposed to the atherogenic stimulus oxidized low-density lipoprotein (OxLDL) exhibited enhanced HDAC6 activity, which was attenuated by pretreatment with MLN4924.	pevonedistat	169-176	histone deacetylase 6	Mus musculus	111-116
35634959-5	2022	Polymerase chain reaction analysis determined IL-23 expression in cyclin-dependent kinase 2 (Cdk2) short hairpin RNA (shRNA)-pretreated or DDB1-cullin-4-associated factor-2 (DCAF2)-overexpressed RAW264.7 cells or CDKs inhibitor AT7519/cullin ring-finger ubiquitin ligase inhibitor MLN4924-treated bone marrow-derived macrophages in the presence of lipopolysaccharides (LPS).	pevonedistat	281-288	interleukin 23, alpha subunit p19	Mus musculus	46-51
35578798-4	2022	Further, the inactivation of neddylation by MLN4924 caused the accumulation of the cullin ring ligase (CRLs) substrates Wee1 and c-Myc, which could upregulate NOXA protein expression.	pevonedistat	44-51	wee1-like protein kinase	Ovis aries	120-124
35578798-8	2022	Neddylation inactivation by MLN4924 increased the levels of phospho-Akt, JAK2, phospho-STAT3, and FOXO1 (p < 0.05) and decreased the levels of phospho-FOXO3a and STAT3 (p < 0.05).	pevonedistat	28-35	forkhead box protein O1	Ovis aries	98-103
35578798-8	2022	Neddylation inactivation by MLN4924 increased the levels of phospho-Akt, JAK2, phospho-STAT3, and FOXO1 (p < 0.05) and decreased the levels of phospho-FOXO3a and STAT3 (p < 0.05).	pevonedistat	28-35	signal transducer and activator of transcription 3	Ovis aries	162-167
35428693-7	2022	However, inactivation of the NEDD8-conugation machinery by treating cells with MLN4924 inhibited the presentation of peptides from the defective ribosomal product-derived form of a model Ag.	pevonedistat	79-86	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	29-34
35545257-3	2022	In this study, we demonstrate this interplay in the CLH and DDI effect in the presence of CYP3A4 perpetrator for pevonedistat using both the Conventional Clearance Model (CCM) and the Extended Clearance Model (ECM).	pevonedistat	113-125	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96
35545257-4	2022	In Vitro metabolism and hepatocyte uptake data showed that pevonedistat is actively transported into the liver via multiple uptake transporters and metabolized predominantly by CYP3A4 (88%).	pevonedistat	59-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	177-183
35545778-1	2022	Pevonedistat, the first small-molecule inhibitor of NEDD8-activating enzyme, has demonstrated clinical activity in Western patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).	pevonedistat	0-12	NEDD8 ubiquitin like modifier	Homo sapiens	52-57
35504658-1	2022	Metabolism and disposition of pevonedistat, an investigational, first-in-class inhibitor of the NEDD8-activating enzyme (NAE), were characterized in patients with advanced solid tumors after intravenous infusion of (14C)pevonedistat at 25 mg/m2 (~60-85mCi radioactive dose).	pevonedistat	30-42	NEDD8 ubiquitin like modifier	Homo sapiens	96-101
35504658-10	2022	Reaction phenotyping studies revealed that CYP3A4/5 are primary enzymes responsible for the metabolic clearance of pevonedistat.	pevonedistat	115-127	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-51
35504658-11	2022	Significance Statement This study details the metabolism and clearance mechanisms of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, after intravenous administration to patients with cancer.	pevonedistat	85-97	NEDD8 ubiquitin like modifier	Homo sapiens	116-121
35578798-4	2022	Further, the inactivation of neddylation by MLN4924 caused the accumulation of the cullin ring ligase (CRLs) substrates Wee1 and c-Myc, which could upregulate NOXA protein expression.	pevonedistat	44-51	myc proto-oncogene protein	Ovis aries	129-134
35578798-8	2022	Neddylation inactivation by MLN4924 increased the levels of phospho-Akt, JAK2, phospho-STAT3, and FOXO1 (p < 0.05) and decreased the levels of phospho-FOXO3a and STAT3 (p < 0.05).	pevonedistat	28-35	RAC-alpha serine/threonine-protein kinase	Ovis aries	68-71
35578798-8	2022	Neddylation inactivation by MLN4924 increased the levels of phospho-Akt, JAK2, phospho-STAT3, and FOXO1 (p < 0.05) and decreased the levels of phospho-FOXO3a and STAT3 (p < 0.05).	pevonedistat	28-35	tyrosine-protein kinase JAK2	Ovis aries	73-77
35578798-8	2022	Neddylation inactivation by MLN4924 increased the levels of phospho-Akt, JAK2, phospho-STAT3, and FOXO1 (p < 0.05) and decreased the levels of phospho-FOXO3a and STAT3 (p < 0.05).	pevonedistat	28-35	signal transducer and activator of transcription 3	Ovis aries	87-92
35320710-3	2022	We demonstrate that N-terminal phosphorylated beta-catenin is quickly and strongly stabilized by a specific neddylation inhibitor, MLN4924, in all examined cell types, and that beta-catenin and TCF4 interaction is strongly enhanced by inhibition of neddylation but not ubiquitylation.	pevonedistat	131-138	catenin beta 1	Homo sapiens	46-58
35519003-8	2022	As CUL4A needs to be activated by neddylation to facilitate the degradation of several proteins including PCNA, we propose a novel explanation for the synergism between cytarabine and the neddylation inhibitor pevonedistat by inhibition of translesion synthesis.	pevonedistat	210-222	cullin 4A	Homo sapiens	3-8
35519003-8	2022	As CUL4A needs to be activated by neddylation to facilitate the degradation of several proteins including PCNA, we propose a novel explanation for the synergism between cytarabine and the neddylation inhibitor pevonedistat by inhibition of translesion synthesis.	pevonedistat	210-222	proliferating cell nuclear antigen	Homo sapiens	106-110
35428778-3	2022	Here we report that HNSCC tumors significantly overexpress NEDD8 and exhibit high sensitivity to the first-in-class NEDD8-activating enzyme (NAE) inhibitor pevonedistat.	pevonedistat	156-168	NEDD8 ubiquitin like modifier	Homo sapiens	59-64
35428778-3	2022	Here we report that HNSCC tumors significantly overexpress NEDD8 and exhibit high sensitivity to the first-in-class NEDD8-activating enzyme (NAE) inhibitor pevonedistat.	pevonedistat	156-168	NEDD8 ubiquitin like modifier	Homo sapiens	116-121
35428778-4	2022	Additional studies established that disruption of NEDD8-mediated protein turnover with pevonedistat dramatically augmented cisplatin-induced DNA damage and apoptosis in HNSCC models.	pevonedistat	87-99	NEDD8 ubiquitin like modifier	Homo sapiens	50-55
35428778-5	2022	Further analysis revealed that the specific pevonedistat target CUL4A played an essential role in driving the synergy of the pevonedistat and cisplatin combination.	pevonedistat	44-56	cullin 4A	Homo sapiens	64-69
35428778-5	2022	Further analysis revealed that the specific pevonedistat target CUL4A played an essential role in driving the synergy of the pevonedistat and cisplatin combination.	pevonedistat	125-137	cullin 4A	Homo sapiens	64-69
35428778-8	2022	Administration of pevonedistat to mice bearing HNSCC tumors significantly decreased DDB2 expression in tumor cells, increased DNA damage and potently enhanced the activity of cisplatin to yield tumor regression and long-term survival of all animals.	pevonedistat	18-30	damage specific DNA binding protein 2	Mus musculus	84-88
35428778-9	2022	Our findings provide strong rationale for clinical investigation of CUL4A inhibition with pevonedistat as a novel strategy to augment the efficacy of cisplatin therapy for patients with HNSCC and identify loss of DDB2 as a key pharmacodynamic mediator controlling sensitivity to this regimen.	pevonedistat	90-102	cullin 4A	Homo sapiens	68-73
35428778-9	2022	Our findings provide strong rationale for clinical investigation of CUL4A inhibition with pevonedistat as a novel strategy to augment the efficacy of cisplatin therapy for patients with HNSCC and identify loss of DDB2 as a key pharmacodynamic mediator controlling sensitivity to this regimen.	pevonedistat	90-102	damage specific DNA binding protein 2	Homo sapiens	213-217
35217064-4	2022	METHODS: levels and function of NEDDylation, together with response to pevonedistat (NEDDylation inhibitor) or CRISPR/Cas9 against NAE1 were evaluated in vitro, in vivo and/or in patients with CCA.	pevonedistat	71-83	NEDD8 activating enzyme E1 subunit 1	Homo sapiens	131-135
35197103-5	2022	RESULTS: In patient-derived MPM cultures and syngenic murine models, MLN4924 and cisplatin showed anti-tumor effects, regardless of MPM histotype and BAP1 mutational status, increasing DNA damage, inducing S- and G2/M-cell cycle arrest, and apoptosis.	pevonedistat	69-76	Brca1 associated protein 1	Mus musculus	150-154
35101976-0	2022	The NEDD8-activating enzyme inhibitor MLN4924 reduces ischemic brain injury in mice.	pevonedistat	38-45	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	4-9
35197103-6	2022	Mechanistically, by interfering with the neddylation of cullin-1 and ubiquitin-conjugating enzyme UBE2M, MLN4924 blocks the SCF complex activity and triggers an ER stress-dependent ICD, which activated anti-MPM CD8+T-lymphocytes.	pevonedistat	105-112	cullin 1	Homo sapiens	56-64
35197103-6	2022	Mechanistically, by interfering with the neddylation of cullin-1 and ubiquitin-conjugating enzyme UBE2M, MLN4924 blocks the SCF complex activity and triggers an ER stress-dependent ICD, which activated anti-MPM CD8+T-lymphocytes.	pevonedistat	105-112	ubiquitin conjugating enzyme E2 M	Homo sapiens	98-103
35197103-6	2022	Mechanistically, by interfering with the neddylation of cullin-1 and ubiquitin-conjugating enzyme UBE2M, MLN4924 blocks the SCF complex activity and triggers an ER stress-dependent ICD, which activated anti-MPM CD8+T-lymphocytes.	pevonedistat	105-112	CD8a molecule	Homo sapiens	211-214
35197103-7	2022	The SKP2 component of SCF complex was identified as the main driver of sensitivity to MLN4924 and resistance to cisplatin.	pevonedistat	86-93	S-phase kinase-associated protein 2	Mus musculus	4-8
35101976-6	2022	MLN4924 treatment induced the accumulation of the CRL substrate neurofibromatosis 1 (NF1).	pevonedistat	0-7	neurofibromin 1	Mus musculus	85-88
35354476-7	2022	In LNCaP and VCaP cells, the stimulation of RhoA and RhoB by MLN4924 markedly upregulates the level of tight junction proteins at cell-cell contacts, which augments the mechanical strain induced by Rho signaling.	pevonedistat	61-68	ras homolog family member A	Homo sapiens	44-48
35354476-7	2022	In LNCaP and VCaP cells, the stimulation of RhoA and RhoB by MLN4924 markedly upregulates the level of tight junction proteins at cell-cell contacts, which augments the mechanical strain induced by Rho signaling.	pevonedistat	61-68	ras homolog family member B	Homo sapiens	53-57
35155257-8	2022	Mechanistically, pevonedistat treatment and the siRNA knockdown neddylation pathway were able to remarkably induce the accumulation of Wee1, p27, and p21.	pevonedistat	17-29	WEE1 G2 checkpoint kinase	Homo sapiens	135-139
35155257-8	2022	Mechanistically, pevonedistat treatment and the siRNA knockdown neddylation pathway were able to remarkably induce the accumulation of Wee1, p27, and p21.	pevonedistat	17-29	dynactin subunit 6	Homo sapiens	141-144
35155257-8	2022	Mechanistically, pevonedistat treatment and the siRNA knockdown neddylation pathway were able to remarkably induce the accumulation of Wee1, p27, and p21.	pevonedistat	17-29	H3 histone pseudogene 16	Homo sapiens	150-153
35155257-10	2022	Conclusions: Our results showed that pevonedistat targeted the overexpression of the neddylation pathway in pancreatic cancer to induce cell growth suppression by inducing the accumulation of the cell cycle regulators Wee1, p27, and p21, which provides sound evidence for the clinical trial of pevonedistat for pancreatic cancer therapy.	pevonedistat	37-49	WEE1 G2 checkpoint kinase	Homo sapiens	218-222
35155257-10	2022	Conclusions: Our results showed that pevonedistat targeted the overexpression of the neddylation pathway in pancreatic cancer to induce cell growth suppression by inducing the accumulation of the cell cycle regulators Wee1, p27, and p21, which provides sound evidence for the clinical trial of pevonedistat for pancreatic cancer therapy.	pevonedistat	37-49	dynactin subunit 6	Homo sapiens	224-227
35155257-10	2022	Conclusions: Our results showed that pevonedistat targeted the overexpression of the neddylation pathway in pancreatic cancer to induce cell growth suppression by inducing the accumulation of the cell cycle regulators Wee1, p27, and p21, which provides sound evidence for the clinical trial of pevonedistat for pancreatic cancer therapy.	pevonedistat	37-49	H3 histone pseudogene 16	Homo sapiens	233-236
35155257-10	2022	Conclusions: Our results showed that pevonedistat targeted the overexpression of the neddylation pathway in pancreatic cancer to induce cell growth suppression by inducing the accumulation of the cell cycle regulators Wee1, p27, and p21, which provides sound evidence for the clinical trial of pevonedistat for pancreatic cancer therapy.	pevonedistat	294-306	WEE1 G2 checkpoint kinase	Homo sapiens	218-222
35101976-8	2022	These effects were mediated through activation of endothelial P-selectin and intercellular adhesion molecule-1 (ICAM-1), and blocking antibodies against P-selectin or anti-ICAM-1 antibodies reversed NF1 silencing-induced increase in neutrophil infiltration in MLN4924-treated mice.	pevonedistat	260-267	selectin, platelet	Mus musculus	153-163
35101976-8	2022	These effects were mediated through activation of endothelial P-selectin and intercellular adhesion molecule-1 (ICAM-1), and blocking antibodies against P-selectin or anti-ICAM-1 antibodies reversed NF1 silencing-induced increase in neutrophil infiltration in MLN4924-treated mice.	pevonedistat	260-267	intercellular adhesion molecule 1	Mus musculus	172-178
35101976-8	2022	These effects were mediated through activation of endothelial P-selectin and intercellular adhesion molecule-1 (ICAM-1), and blocking antibodies against P-selectin or anti-ICAM-1 antibodies reversed NF1 silencing-induced increase in neutrophil infiltration in MLN4924-treated mice.	pevonedistat	260-267	neurofibromin 1	Mus musculus	199-202
35101976-9	2022	Furthermore, we found that NF1 silencing blocked MLN4924-afforded BBB protection and neuroprotection through activation of protein kinase C delta (PKCdelta), myristoylated alanine-rich C-kinase substrate (MARCKS), and myosin light chain (MLC) in cerebral microvessels after ischemic stroke, and treatment of mice with the PKCdelta inhibitor rottlerin reduced this increased BBB permeability.	pevonedistat	49-56	neurofibromin 1	Mus musculus	27-30
35101976-6	2022	MLN4924 treatment induced the accumulation of the CRL substrate neurofibromatosis 1 (NF1).	pevonedistat	0-7	neurofibromin 1	Mus musculus	64-83
35176901-9	2022	In addition, celecoxib potentiated the MLN4924-induced EMT, decreased the expression of N-cadherin and vimentin, and activated the expression of E-cadherin.	pevonedistat	39-46	vimentin	Homo sapiens	103-111
35101976-9	2022	Furthermore, we found that NF1 silencing blocked MLN4924-afforded BBB protection and neuroprotection through activation of protein kinase C delta (PKCdelta), myristoylated alanine-rich C-kinase substrate (MARCKS), and myosin light chain (MLC) in cerebral microvessels after ischemic stroke, and treatment of mice with the PKCdelta inhibitor rottlerin reduced this increased BBB permeability.	pevonedistat	49-56	protein kinase C, delta	Mus musculus	123-145
35101976-9	2022	Furthermore, we found that NF1 silencing blocked MLN4924-afforded BBB protection and neuroprotection through activation of protein kinase C delta (PKCdelta), myristoylated alanine-rich C-kinase substrate (MARCKS), and myosin light chain (MLC) in cerebral microvessels after ischemic stroke, and treatment of mice with the PKCdelta inhibitor rottlerin reduced this increased BBB permeability.	pevonedistat	49-56	protein kinase C, delta	Mus musculus	147-155
35101976-9	2022	Furthermore, we found that NF1 silencing blocked MLN4924-afforded BBB protection and neuroprotection through activation of protein kinase C delta (PKCdelta), myristoylated alanine-rich C-kinase substrate (MARCKS), and myosin light chain (MLC) in cerebral microvessels after ischemic stroke, and treatment of mice with the PKCdelta inhibitor rottlerin reduced this increased BBB permeability.	pevonedistat	49-56	myristoylated alanine rich protein kinase C substrate	Mus musculus	158-203
35101976-9	2022	Furthermore, we found that NF1 silencing blocked MLN4924-afforded BBB protection and neuroprotection through activation of protein kinase C delta (PKCdelta), myristoylated alanine-rich C-kinase substrate (MARCKS), and myosin light chain (MLC) in cerebral microvessels after ischemic stroke, and treatment of mice with the PKCdelta inhibitor rottlerin reduced this increased BBB permeability.	pevonedistat	49-56	myristoylated alanine rich protein kinase C substrate	Mus musculus	205-211
35101976-9	2022	Furthermore, we found that NF1 silencing blocked MLN4924-afforded BBB protection and neuroprotection through activation of protein kinase C delta (PKCdelta), myristoylated alanine-rich C-kinase substrate (MARCKS), and myosin light chain (MLC) in cerebral microvessels after ischemic stroke, and treatment of mice with the PKCdelta inhibitor rottlerin reduced this increased BBB permeability.	pevonedistat	49-56	protein kinase C, delta	Mus musculus	322-330
35176901-0	2022	Celecoxib Synergistically Enhances MLN4924-Induced Cytotoxicity and EMT Inhibition Via AKT and ERK Pathways in Human Urothelial Carcinoma.	pevonedistat	35-42	mitogen-activated protein kinase 1	Homo sapiens	95-98
35176901-1	2022	MLN4924 is a specific small-molecule inhibitor of NEDD8-activating enzyme (NAE) that blocks the neddylation modification cascade.	pevonedistat	0-7	NEDD8 ubiquitin like modifier	Homo sapiens	50-55
35176901-13	2022	It also inhibited the activation of AKT and ERK pathways, which were activated by MLN4924.	pevonedistat	82-89	thymoma viral proto-oncogene 1	Mus musculus	36-39
35176901-3	2022	However, recent studies have also found that MLN4924 activates the PI3K/AKT and MAPK/ERK signal pathways, important regulators of tumorigenesis, and drug resistance in human urothelial carcinoma (UC).	pevonedistat	45-52	AKT serine/threonine kinase 1	Homo sapiens	72-75
35176901-13	2022	It also inhibited the activation of AKT and ERK pathways, which were activated by MLN4924.	pevonedistat	82-89	mitogen-activated protein kinase 1	Mus musculus	44-47
35176901-3	2022	However, recent studies have also found that MLN4924 activates the PI3K/AKT and MAPK/ERK signal pathways, important regulators of tumorigenesis, and drug resistance in human urothelial carcinoma (UC).	pevonedistat	45-52	mitogen-activated protein kinase 1	Homo sapiens	85-88
35176901-6	2022	Briefly, a combination of MLN4924 and celecoxib reduced the protein expression of p-AKT(S473) and p-ERK in UC cell lines.	pevonedistat	26-33	AKT serine/threonine kinase 1	Homo sapiens	84-87
33279641-0	2021	The CUL3/neddylation inhibitor MLN4924 reduces ethanol-induced locomotor sensitization and inflammatory pain allodynia in mice.	pevonedistat	31-38	cullin 3	Mus musculus	4-8
35176901-6	2022	Briefly, a combination of MLN4924 and celecoxib reduced the protein expression of p-AKT(S473) and p-ERK in UC cell lines.	pevonedistat	26-33	mitogen-activated protein kinase 1	Homo sapiens	100-103
33898451-3	2021	Upregulation of the neddylation pathway is closely associated with the progression of various tumors, and MLN4924, which inhibits NEDD8-activating enzyme (NAE), is a promising new antitumor compound for combination therapy.	pevonedistat	106-113	NEDD8 ubiquitin like modifier	Homo sapiens	130-135
33723230-4	2021	The increased M2 macrophage infiltration, mediated by the upregulated chemokine (C-C motif) ligand 5 (CCL5), is responsible for the enhanced pancreatitis-promoting activity of MLN4924.	pevonedistat	176-183	C-C motif chemokine ligand 5	Homo sapiens	70-100
33723230-4	2021	The increased M2 macrophage infiltration, mediated by the upregulated chemokine (C-C motif) ligand 5 (CCL5), is responsible for the enhanced pancreatitis-promoting activity of MLN4924.	pevonedistat	176-183	C-C motif chemokine ligand 5	Homo sapiens	102-106
33723230-5	2021	Both CCL5 blockade and macrophage depletion contribute to alleviating pancreatic fibrosis and inflammation in MLN4924-treated CP mice.	pevonedistat	110-117	chemokine (C-C motif) ligand 5	Mus musculus	5-9
33374005-7	2021	Finally, we demonstrated that inhibition of NEDD8 activating enzyme using the specific inhibitor pevonedistat (MLN4924) significantly ameliorated disease severity in murine experimental autoimmune encephalomyelitis.	pevonedistat	97-109	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	44-49
33374005-7	2021	Finally, we demonstrated that inhibition of NEDD8 activating enzyme using the specific inhibitor pevonedistat (MLN4924) significantly ameliorated disease severity in murine experimental autoimmune encephalomyelitis.	pevonedistat	111-118	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	44-49
33572115-3	2021	Here, we report that MLN4924 inhibits tumor necrosis factor-alpha (TNF-alpha)-induced matrix metalloproteinase 9 (MMP9)-driven cell migration.	pevonedistat	21-28	tumor necrosis factor	Homo sapiens	38-65
33572115-3	2021	Here, we report that MLN4924 inhibits tumor necrosis factor-alpha (TNF-alpha)-induced matrix metalloproteinase 9 (MMP9)-driven cell migration.	pevonedistat	21-28	tumor necrosis factor	Homo sapiens	67-76
33572115-3	2021	Here, we report that MLN4924 inhibits tumor necrosis factor-alpha (TNF-alpha)-induced matrix metalloproteinase 9 (MMP9)-driven cell migration.	pevonedistat	21-28	matrix metallopeptidase 9	Homo sapiens	86-112
33572115-3	2021	Here, we report that MLN4924 inhibits tumor necrosis factor-alpha (TNF-alpha)-induced matrix metalloproteinase 9 (MMP9)-driven cell migration.	pevonedistat	21-28	matrix metallopeptidase 9	Homo sapiens	114-118
33572115-4	2021	Using real-time polymerase chain reaction (PCR) and gelatin zymography, we found that MLN4924 inhibited expression and activity of MMP9 at the messenger RNA (mRNA) and protein levels in both resting cells and cells stimulated with TNF-alpha, and this inhibition was closely related to impaired cell migration.	pevonedistat	86-93	matrix metallopeptidase 9	Homo sapiens	131-135
33572115-4	2021	Using real-time polymerase chain reaction (PCR) and gelatin zymography, we found that MLN4924 inhibited expression and activity of MMP9 at the messenger RNA (mRNA) and protein levels in both resting cells and cells stimulated with TNF-alpha, and this inhibition was closely related to impaired cell migration.	pevonedistat	86-93	tumor necrosis factor	Homo sapiens	231-240
33572115-5	2021	We also revealed that MLN4924, similar to TNF-alpha, induced phosphorylation of inhibitor of nuclear factor kappa B-alpha (IkappaB-alpha).	pevonedistat	22-29	NFKB inhibitor alpha	Homo sapiens	123-136
33572115-7	2021	In coimmunoprecipitation experiments, nuclear IkappaB-alpha which formed complexes with nuclear factor kappa B p65 subunit (NFkappaB/p65) was found to be highly phosphorylated at Ser32 in the cells treated with MLN4924, but not in the cells treated with TNF-alpha alone.	pevonedistat	211-218	NFKB inhibitor alpha	Homo sapiens	46-59
33572115-7	2021	In coimmunoprecipitation experiments, nuclear IkappaB-alpha which formed complexes with nuclear factor kappa B p65 subunit (NFkappaB/p65) was found to be highly phosphorylated at Ser32 in the cells treated with MLN4924, but not in the cells treated with TNF-alpha alone.	pevonedistat	211-218	RELA proto-oncogene, NF-kB subunit	Homo sapiens	88-136
33572115-7	2021	In coimmunoprecipitation experiments, nuclear IkappaB-alpha which formed complexes with nuclear factor kappa B p65 subunit (NFkappaB/p65) was found to be highly phosphorylated at Ser32 in the cells treated with MLN4924, but not in the cells treated with TNF-alpha alone.	pevonedistat	211-218	tumor necrosis factor	Homo sapiens	254-263
33572115-8	2021	Moreover, in the presence of MLN4924, nuclear NFkappaB/p65 complexes were found to be enriched in c-Jun and cyclin dependent kinase inhibitor 1 A (CDKN1A/p21) proteins.	pevonedistat	29-36	nuclear factor kappa B subunit 1	Homo sapiens	46-54
33572115-8	2021	Moreover, in the presence of MLN4924, nuclear NFkappaB/p65 complexes were found to be enriched in c-Jun and cyclin dependent kinase inhibitor 1 A (CDKN1A/p21) proteins.	pevonedistat	29-36	RELA proto-oncogene, NF-kB subunit	Homo sapiens	55-58
33572115-8	2021	Moreover, in the presence of MLN4924, nuclear NFkappaB/p65 complexes were found to be enriched in c-Jun and cyclin dependent kinase inhibitor 1 A (CDKN1A/p21) proteins.	pevonedistat	29-36	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	98-103
33572115-8	2021	Moreover, in the presence of MLN4924, nuclear NFkappaB/p65 complexes were found to be enriched in c-Jun and cyclin dependent kinase inhibitor 1 A (CDKN1A/p21) proteins.	pevonedistat	29-36	cyclin dependent kinase inhibitor 1A	Homo sapiens	108-145
33572115-8	2021	Moreover, in the presence of MLN4924, nuclear NFkappaB/p65 complexes were found to be enriched in c-Jun and cyclin dependent kinase inhibitor 1 A (CDKN1A/p21) proteins.	pevonedistat	29-36	cyclin dependent kinase inhibitor 1A	Homo sapiens	147-153
33572115-8	2021	Moreover, in the presence of MLN4924, nuclear NFkappaB/p65 complexes were found to be enriched in c-Jun and cyclin dependent kinase inhibitor 1 A (CDKN1A/p21) proteins.	pevonedistat	29-36	cyclin dependent kinase inhibitor 1A	Homo sapiens	154-157
33572115-10	2021	Taken together, our findings identified MLN4924 as a suppressor of TNF-alpha-induced MMP9-driven cell migration in esophageal squamous cell carcinoma (ESCC), likely acting by affecting the nuclear ubiquitin-proteasome system that governs NFkappaB/p65 complex formation and its DNA binding activity in regard to the MMP9 promoter, suggesting that inhibition of neddylation might be a new therapeutic strategy to prevent invasion/metastasis in ESCC patients.	pevonedistat	40-47	tumor necrosis factor	Homo sapiens	67-76
33572115-10	2021	Taken together, our findings identified MLN4924 as a suppressor of TNF-alpha-induced MMP9-driven cell migration in esophageal squamous cell carcinoma (ESCC), likely acting by affecting the nuclear ubiquitin-proteasome system that governs NFkappaB/p65 complex formation and its DNA binding activity in regard to the MMP9 promoter, suggesting that inhibition of neddylation might be a new therapeutic strategy to prevent invasion/metastasis in ESCC patients.	pevonedistat	40-47	matrix metallopeptidase 9	Homo sapiens	85-89
33572115-10	2021	Taken together, our findings identified MLN4924 as a suppressor of TNF-alpha-induced MMP9-driven cell migration in esophageal squamous cell carcinoma (ESCC), likely acting by affecting the nuclear ubiquitin-proteasome system that governs NFkappaB/p65 complex formation and its DNA binding activity in regard to the MMP9 promoter, suggesting that inhibition of neddylation might be a new therapeutic strategy to prevent invasion/metastasis in ESCC patients.	pevonedistat	40-47	nuclear factor kappa B subunit 1	Homo sapiens	238-246
33572115-10	2021	Taken together, our findings identified MLN4924 as a suppressor of TNF-alpha-induced MMP9-driven cell migration in esophageal squamous cell carcinoma (ESCC), likely acting by affecting the nuclear ubiquitin-proteasome system that governs NFkappaB/p65 complex formation and its DNA binding activity in regard to the MMP9 promoter, suggesting that inhibition of neddylation might be a new therapeutic strategy to prevent invasion/metastasis in ESCC patients.	pevonedistat	40-47	RELA proto-oncogene, NF-kB subunit	Homo sapiens	247-250
33572115-10	2021	Taken together, our findings identified MLN4924 as a suppressor of TNF-alpha-induced MMP9-driven cell migration in esophageal squamous cell carcinoma (ESCC), likely acting by affecting the nuclear ubiquitin-proteasome system that governs NFkappaB/p65 complex formation and its DNA binding activity in regard to the MMP9 promoter, suggesting that inhibition of neddylation might be a new therapeutic strategy to prevent invasion/metastasis in ESCC patients.	pevonedistat	40-47	matrix metallopeptidase 9	Homo sapiens	315-319
33199266-5	2021	MLN4924, an inhibitor of NEDD8-activating enzyme, inhibited neddylation of Cullin3 and reversed the reduction of Na/K-ATPase alpha1 expression caused by 20-HETE.	pevonedistat	0-7	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	25-30
33199266-5	2021	MLN4924, an inhibitor of NEDD8-activating enzyme, inhibited neddylation of Cullin3 and reversed the reduction of Na/K-ATPase alpha1 expression caused by 20-HETE.	pevonedistat	0-7	cullin 3	Mus musculus	75-82
34644371-9	2022	These studies demonstrating efficacy of pevonedistat in MPN cells in vitro as well as in vivo provide a rationale for therapeutic inhibition of NFkappaB signaling for MF treatment.	pevonedistat	40-52	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	144-152
33996822-0	2021	The Absence of PTEN in Breast Cancer Is a Driver of MLN4924 Resistance.	pevonedistat	52-59	phosphatase and tensin homolog	Homo sapiens	15-19
33996822-2	2021	MLN4924 (Pevonedistat), an inhibitor of the NEDD8-activating E1 enzyme, is considered a promising chemotherapeutic agent.	pevonedistat	0-7	NEDD8 ubiquitin like modifier	Homo sapiens	44-49
33996822-2	2021	MLN4924 (Pevonedistat), an inhibitor of the NEDD8-activating E1 enzyme, is considered a promising chemotherapeutic agent.	pevonedistat	9-21	NEDD8 ubiquitin like modifier	Homo sapiens	44-49
33996822-12	2021	Results: Our data show that the anti-tumor efficacy of MLN4924 in breast cancer cells was markedly reduced with the deletion of PTEN.	pevonedistat	55-62	phosphatase and tensin homolog	Homo sapiens	128-132
33996822-17	2021	PTEN is critical, if not indispensable, for MLN4924 suppression of tumor growth; PTEN status thus may help to identify MLN4924-responsive breast cancer patients.	pevonedistat	44-51	phosphatase and tensin homolog	Homo sapiens	0-4
33911083-8	2021	The CRL neddylation inhibitor Pevonedistat/MLN4924 stabilizes ETV5 and remediates the hyperinsulinemia and obesity/diabetes phenotypes of these mice.	pevonedistat	30-42	ets variant 5	Mus musculus	62-66
33911083-8	2021	The CRL neddylation inhibitor Pevonedistat/MLN4924 stabilizes ETV5 and remediates the hyperinsulinemia and obesity/diabetes phenotypes of these mice.	pevonedistat	43-50	ets variant 5	Mus musculus	62-66
33853293-0	2022	Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia.	pevonedistat	0-12	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	40-44
33853293-0	2022	Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia.	pevonedistat	0-12	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	46-52
33853293-6	2022	Pevonedistat (PEV), a novel agent that inhibits NEDD8-activating enzyme, and AZA both upregulate NOXA (PMAIP1), a BCL2 family protein that competes with effector molecules at the BH3 binding site of MCL1.	pevonedistat	0-12	NEDD8 ubiquitin like modifier	Homo sapiens	48-53
33853293-6	2022	Pevonedistat (PEV), a novel agent that inhibits NEDD8-activating enzyme, and AZA both upregulate NOXA (PMAIP1), a BCL2 family protein that competes with effector molecules at the BH3 binding site of MCL1.	pevonedistat	0-12	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	97-101
33853293-6	2022	Pevonedistat (PEV), a novel agent that inhibits NEDD8-activating enzyme, and AZA both upregulate NOXA (PMAIP1), a BCL2 family protein that competes with effector molecules at the BH3 binding site of MCL1.	pevonedistat	0-12	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	103-109
33853293-6	2022	Pevonedistat (PEV), a novel agent that inhibits NEDD8-activating enzyme, and AZA both upregulate NOXA (PMAIP1), a BCL2 family protein that competes with effector molecules at the BH3 binding site of MCL1.	pevonedistat	0-12	BCL2 apoptosis regulator	Homo sapiens	114-118
33853293-6	2022	Pevonedistat (PEV), a novel agent that inhibits NEDD8-activating enzyme, and AZA both upregulate NOXA (PMAIP1), a BCL2 family protein that competes with effector molecules at the BH3 binding site of MCL1.	pevonedistat	0-12	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	199-203
33853293-6	2022	Pevonedistat (PEV), a novel agent that inhibits NEDD8-activating enzyme, and AZA both upregulate NOXA (PMAIP1), a BCL2 family protein that competes with effector molecules at the BH3 binding site of MCL1.	pevonedistat	14-17	NEDD8 ubiquitin like modifier	Homo sapiens	48-53
33853293-6	2022	Pevonedistat (PEV), a novel agent that inhibits NEDD8-activating enzyme, and AZA both upregulate NOXA (PMAIP1), a BCL2 family protein that competes with effector molecules at the BH3 binding site of MCL1.	pevonedistat	14-17	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	97-101
33853293-6	2022	Pevonedistat (PEV), a novel agent that inhibits NEDD8-activating enzyme, and AZA both upregulate NOXA (PMAIP1), a BCL2 family protein that competes with effector molecules at the BH3 binding site of MCL1.	pevonedistat	14-17	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	103-109
33853293-6	2022	Pevonedistat (PEV), a novel agent that inhibits NEDD8-activating enzyme, and AZA both upregulate NOXA (PMAIP1), a BCL2 family protein that competes with effector molecules at the BH3 binding site of MCL1.	pevonedistat	14-17	BCL2 apoptosis regulator	Homo sapiens	114-118
33853293-6	2022	Pevonedistat (PEV), a novel agent that inhibits NEDD8-activating enzyme, and AZA both upregulate NOXA (PMAIP1), a BCL2 family protein that competes with effector molecules at the BH3 binding site of MCL1.	pevonedistat	14-17	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	199-203
33918652-7	2021	Though the fusion of NEDD8 to a protein resulted in degradation, treatment of cells with MLN4924, an inhibitor of the E1 activating enzyme for NEDD8, failed to prevent degradation of other destabilized substrates.	pevonedistat	89-96	NEDD8 ubiquitin like modifier	Homo sapiens	143-148
33089874-1	2021	Pevonedistat (TAK-924/MLN4924) is an investigational small-molecule inhibitor of the NEDD8-activating enzyme that has demonstrated preclinical and clinical activity across solid tumors and hematological malignancies.	pevonedistat	0-12	NEDD8 ubiquitin like modifier	Homo sapiens	85-90
33089874-1	2021	Pevonedistat (TAK-924/MLN4924) is an investigational small-molecule inhibitor of the NEDD8-activating enzyme that has demonstrated preclinical and clinical activity across solid tumors and hematological malignancies.	pevonedistat	22-29	NEDD8 ubiquitin like modifier	Homo sapiens	85-90
33720974-4	2021	Blocking neddylation pathway using neddylation inhibitor MLN4924 substantially impaired the induction of type I interferon and proinflammatory cytokines, which was selectively dependent on Nedd8 E2 enzyme Ube2m.	pevonedistat	57-64	ubiquitin conjugating enzyme E2 M	Homo sapiens	205-210
33432425-6	2021	Moreover, decreased KLHL3 was reversed and WNK1 and WNK4 abundance increased by MLN4924, a neddylation inhibitor.	pevonedistat	80-87	kelch-like 3	Mus musculus	20-25
33432425-6	2021	Moreover, decreased KLHL3 was reversed and WNK1 and WNK4 abundance increased by MLN4924, a neddylation inhibitor.	pevonedistat	80-87	WNK lysine deficient protein kinase 1	Mus musculus	43-47
33432425-6	2021	Moreover, decreased KLHL3 was reversed and WNK1 and WNK4 abundance increased by MLN4924, a neddylation inhibitor.	pevonedistat	80-87	WNK lysine deficient protein kinase 4	Mus musculus	52-56
33279641-4	2021	We also showed that pharmacological inhibition of Cullin3 with the neddylation inhibitor, MLN4924, abolished heterologous sensitization of several AC isoforms, including AC1, AC2, AC5, and AC6.	pevonedistat	90-97	cullin 3	Mus musculus	50-57
33279641-4	2021	We also showed that pharmacological inhibition of Cullin3 with the neddylation inhibitor, MLN4924, abolished heterologous sensitization of several AC isoforms, including AC1, AC2, AC5, and AC6.	pevonedistat	90-97	adenylate cyclase 1	Mus musculus	170-173
33279641-4	2021	We also showed that pharmacological inhibition of Cullin3 with the neddylation inhibitor, MLN4924, abolished heterologous sensitization of several AC isoforms, including AC1, AC2, AC5, and AC6.	pevonedistat	90-97	adenylate cyclase 5	Mus musculus	180-183
33279641-4	2021	We also showed that pharmacological inhibition of Cullin3 with the neddylation inhibitor, MLN4924, abolished heterologous sensitization of several AC isoforms, including AC1, AC2, AC5, and AC6.	pevonedistat	90-97	adenylate cyclase 6	Mus musculus	189-192
33381997-4	2021	We show that spironolactone induces a dose- and time-dependent degradation of XPB but not XPD, and that the XPB degradation is blocked by VCP/p97 inhibitors DBeQ, NMS-873, and neddylation inhibitor MLN4924.	pevonedistat	198-205	ERCC excision repair 3, TFIIH core complex helicase subunit	Homo sapiens	108-111
33503305-1	2021	The investigational NEDD8-activating enzyme inhibitor pevonedistat is being evaluated in combination with azacitidine vs. single-agent azacitidine in patients with higher-risk myelodysplastic syndrome (higher-risk MDS), higher-risk chronic myelomonocytic leukemia (higher-risk CMML), or low-blast acute myeloid leukemia (AML) in a phase III trial PANTHER.	pevonedistat	54-66	NEDD8 ubiquitin like modifier	Homo sapiens	20-25
33381997-4	2021	We show that spironolactone induces a dose- and time-dependent degradation of XPB but not XPD, and that the XPB degradation is blocked by VCP/p97 inhibitors DBeQ, NMS-873, and neddylation inhibitor MLN4924.	pevonedistat	198-205	valosin containing protein	Homo sapiens	138-145
32203139-3	2021	We and others have shown that pevonedistat (TAK-924), a small-molecule inhibitor of NAE, abrogates NF-kappaB signaling in malignant B cells.	pevonedistat	30-42	nuclear factor kappa B subunit 1	Homo sapiens	99-108
33263949-0	2021	Neddylation inhibitor MLN4924 has anti-HBV activity via modulating the ERK-HNF1alpha-C/EBPalpha-HNF4alpha axis.	pevonedistat	22-29	CCAAT enhancer binding protein alpha	Homo sapiens	85-95
32721435-0	2020	The NEDD8-activating enzyme inhibition with MLN4924 sensitizes human cancer cells of different origins to apoptosis and necroptosis.	pevonedistat	44-51	NEDD8 ubiquitin like modifier	Homo sapiens	4-9
32449166-6	2020	MLN4924 (an inhibitor of the NEDD8-activating enzyme-E1) treatment or UBC12 knockdown prevented SREBP-1 neddylation and tumor cell phenotype change.	pevonedistat	0-7	NEDD8 ubiquitin like modifier	Homo sapiens	29-34
32449166-6	2020	MLN4924 (an inhibitor of the NEDD8-activating enzyme-E1) treatment or UBC12 knockdown prevented SREBP-1 neddylation and tumor cell phenotype change.	pevonedistat	0-7	sterol regulatory element binding transcription factor 1	Homo sapiens	96-103
32449166-12	2020	Additionally, MLN4924 treatment destabilized SREBP-1 in MDA-MB-231 breast cancer cells and in the tumor cell xenograft.	pevonedistat	14-21	sterol regulatory element binding transcription factor 1	Homo sapiens	45-52
32449166-15	2020	In summary, SREBP-1 is neddylated by UBC12, which may contribute to HCC and breast cancer aggressiveness through SREBP-1 stabilization, and these events can be intervented by MLN4924 therapy.	pevonedistat	175-182	sterol regulatory element binding transcription factor 1	Homo sapiens	12-19
32449166-15	2020	In summary, SREBP-1 is neddylated by UBC12, which may contribute to HCC and breast cancer aggressiveness through SREBP-1 stabilization, and these events can be intervented by MLN4924 therapy.	pevonedistat	175-182	ubiquitin conjugating enzyme E2 M	Homo sapiens	37-42
33195347-9	2020	Correspondingly, inhibiting neddylation via MLN4924, a small molecule compound targeting NEDD8-activating enzyme (NAE), can potently alleviate CLD progression and improve the outcome.	pevonedistat	44-51	NEDD8 ubiquitin like modifier	Homo sapiens	89-94
32779270-4	2020	Blockage of neddylation with MLN4924, a small molecule inhibitor of neddylation-activating enzyme, destabilizes RPS27L and RPS27 by shortening their protein half-lives.	pevonedistat	29-36	ribosomal protein S27 like	Homo sapiens	112-118
32779270-4	2020	Blockage of neddylation with MLN4924, a small molecule inhibitor of neddylation-activating enzyme, destabilizes RPS27L and RPS27 by shortening their protein half-lives.	pevonedistat	29-36	ribosomal protein S27	Homo sapiens	112-117
32779270-5	2020	Biologically, knockdown of RPS27L and RPS27 sensitizes, whereas ectopic expression of RPS27L and RPS27 desensitizes cancer cells to MLN4924-induced apoptosis.	pevonedistat	132-139	ribosomal protein S27 like	Homo sapiens	86-92
32721435-5	2020	The impact of NAE inhibition with MLN4924 on TNF-induced apoptosis and necroptosis was evaluated using zVAD-fmk and nec-1, respectively.	pevonedistat	34-41	tumor necrosis factor	Homo sapiens	45-48
32721435-7	2020	Also, MLN4924 sensitized different cancer cell lines to TNF-induced cell death.	pevonedistat	6-13	tumor necrosis factor	Homo sapiens	56-59
32721435-8	2020	MLN4924/TNF-induced cell death was apoptosis and necroptosis dependent that may be attributed to MLN4924 inhibition of NF-kappaB pathway activation.	pevonedistat	0-7	tumor necrosis factor	Homo sapiens	8-11
32721435-8	2020	MLN4924/TNF-induced cell death was apoptosis and necroptosis dependent that may be attributed to MLN4924 inhibition of NF-kappaB pathway activation.	pevonedistat	0-7	nuclear factor kappa B subunit 1	Homo sapiens	119-128
32721435-1	2020	OBJECTIVES: MLN4924 is an inhibitor of NEDD8-activating enzyme (NAE) that interferes with the cullin-RING ubiquitin ligase complexes formation and the nuclear factor kappa B (NF-kappaB) activation.	pevonedistat	12-19	NEDD8 ubiquitin like modifier	Homo sapiens	39-44
32721435-8	2020	MLN4924/TNF-induced cell death was apoptosis and necroptosis dependent that may be attributed to MLN4924 inhibition of NF-kappaB pathway activation.	pevonedistat	97-104	tumor necrosis factor	Homo sapiens	8-11
32721435-8	2020	MLN4924/TNF-induced cell death was apoptosis and necroptosis dependent that may be attributed to MLN4924 inhibition of NF-kappaB pathway activation.	pevonedistat	97-104	nuclear factor kappa B subunit 1	Homo sapiens	119-128
32721435-1	2020	OBJECTIVES: MLN4924 is an inhibitor of NEDD8-activating enzyme (NAE) that interferes with the cullin-RING ubiquitin ligase complexes formation and the nuclear factor kappa B (NF-kappaB) activation.	pevonedistat	12-19	nuclear factor kappa B subunit 1	Homo sapiens	151-173
32721435-9	2020	CONCLUSIONS: Thus, targeting NAE and NF-kappaB pathway with MLN4924 represents a substantial approach to enhance sensitivity of cancer cells.	pevonedistat	60-67	nuclear factor kappa B subunit 1	Homo sapiens	37-46
32721435-1	2020	OBJECTIVES: MLN4924 is an inhibitor of NEDD8-activating enzyme (NAE) that interferes with the cullin-RING ubiquitin ligase complexes formation and the nuclear factor kappa B (NF-kappaB) activation.	pevonedistat	12-19	nuclear factor kappa B subunit 1	Homo sapiens	175-184
32721435-2	2020	Here, we investigated the cytotoxic effect of MLN4924 and its ability to sensitize broad range of cancer cells of different origins to TNF-induced cell death alongside unravelling its mechanism of action.	pevonedistat	46-53	tumor necrosis factor	Homo sapiens	135-138
32721435-4	2020	Moreover, MLN4924 ability to potentiate TNF-induced cell death was evaluated in 24 cell lines of different cancer origins.	pevonedistat	10-17	tumor necrosis factor	Homo sapiens	40-43
32313199-5	2020	Inhibiting Cullin-1"s DISC recruitment using the NEDDylation inhibitor MLN4924 (Pevonedistat) or siRNA increased apoptosis induction in response to TRAIL.	pevonedistat	71-78	cullin 1	Homo sapiens	11-19
31665821-1	2020	MLN4924 (pevonedistat) is a potent and selective NEDD8-activating enzyme (NAE) inhibitor.	pevonedistat	0-7	NEDD8 ubiquitin like modifier	Canis lupus familiaris	49-54
32983997-3	2020	Several preclinical studies have demonstrated the efficacy of MLN4924 as a radiosensitizer, mainly due to its unique cytotoxic properties, including induction of DNA damage response, cell cycle checkpoints dysregulation, and inhibition of NF-kappaB and mTOR pathways.	pevonedistat	62-69	nuclear factor kappa B subunit 1	Homo sapiens	239-248
32983997-3	2020	Several preclinical studies have demonstrated the efficacy of MLN4924 as a radiosensitizer, mainly due to its unique cytotoxic properties, including induction of DNA damage response, cell cycle checkpoints dysregulation, and inhibition of NF-kappaB and mTOR pathways.	pevonedistat	62-69	mechanistic target of rapamycin kinase	Homo sapiens	253-257
32641480-3	2020	DFO and MLN-4924, but not FG-4592, induced accumulation of both lytic EBV proteins and phosphorylated p53 in cell lines that contain a wild-type p53 gene.	pevonedistat	8-16	tumor protein p53	Homo sapiens	102-105
32641480-3	2020	DFO and MLN-4924, but not FG-4592, induced accumulation of both lytic EBV proteins and phosphorylated p53 in cell lines that contain a wild-type p53 gene.	pevonedistat	8-16	tumor protein p53	Homo sapiens	145-148
32839427-4	2020	Consistently, using in vitro and in vivo models, we demonstrated that MLN4924, a specific small molecule inhibitor of NEDDylation, can restore ERRbeta expression and culminate in a reduction in cell proliferation and migration of breast cancer cells.	pevonedistat	70-77	estrogen related receptor alpha	Homo sapiens	143-150
32839427-8	2020	Collectively, our work revealed that restoration of ERRbeta expression using the NEDDylation inhibitor MLN4924 can be a novel and effective strategy for breast cancer treatment.	pevonedistat	103-110	estrogen related receptor alpha	Homo sapiens	52-59
32313199-5	2020	Inhibiting Cullin-1"s DISC recruitment using the NEDDylation inhibitor MLN4924 (Pevonedistat) or siRNA increased apoptosis induction in response to TRAIL.	pevonedistat	71-78	TNF superfamily member 10	Homo sapiens	148-153
32313199-5	2020	Inhibiting Cullin-1"s DISC recruitment using the NEDDylation inhibitor MLN4924 (Pevonedistat) or siRNA increased apoptosis induction in response to TRAIL.	pevonedistat	80-92	cullin 1	Homo sapiens	11-19
32313199-5	2020	Inhibiting Cullin-1"s DISC recruitment using the NEDDylation inhibitor MLN4924 (Pevonedistat) or siRNA increased apoptosis induction in response to TRAIL.	pevonedistat	80-92	TNF superfamily member 10	Homo sapiens	148-153
32493769-0	2020	Suramin and NF449 are IP5K inhibitors that disrupt IP6-mediated regulation of cullin RING ligase and sensitize cancer cells to MLN4924/pevonedistat.	pevonedistat	127-134	inositol-pentakisphosphate 2-kinase	Homo sapiens	22-26
31907687-2	2020	Our previous study showed MLN4924, an inhibitor of NEDD8 activating enzyme (E1), significantly inhibits the growth of multiple cancer cells.	pevonedistat	26-33	NEDD8 ubiquitin like modifier	Homo sapiens	51-56
32850489-6	2020	This reduction of SAMHD1 was effectively blocked by MLN4924, an inhibitor of the Cullin-RING-E3 ligase (CRL) complexes, but not by bafilomycin A1, an inhibitor of vacuolar-type H+-ATPase.	pevonedistat	52-59	SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1	Homo sapiens	18-24
32493769-0	2020	Suramin and NF449 are IP5K inhibitors that disrupt IP6-mediated regulation of cullin RING ligase and sensitize cancer cells to MLN4924/pevonedistat.	pevonedistat	135-147	inositol-pentakisphosphate 2-kinase	Homo sapiens	22-26
32493769-8	2020	Finally, nontoxic doses of suramin, NF449, or NF110 exacerbates the loss of cell viability elicited by the neddylation inhibitor and clinical trial drug MLN4924/pevonedistat, suggesting synergistic effects.	pevonedistat	153-160	interleukin enhancer binding factor 3	Homo sapiens	46-51
32493769-8	2020	Finally, nontoxic doses of suramin, NF449, or NF110 exacerbates the loss of cell viability elicited by the neddylation inhibitor and clinical trial drug MLN4924/pevonedistat, suggesting synergistic effects.	pevonedistat	161-173	interleukin enhancer binding factor 3	Homo sapiens	46-51
32493769-9	2020	Suramin and its analogs provide structural templates for designing potent and specific IP5K inhibitors, which could be used in combination therapy along with MLN4924/pevonedistat.	pevonedistat	158-165	inositol-pentakisphosphate 2-kinase	Homo sapiens	87-91
32493769-9	2020	Suramin and its analogs provide structural templates for designing potent and specific IP5K inhibitors, which could be used in combination therapy along with MLN4924/pevonedistat.	pevonedistat	166-178	inositol-pentakisphosphate 2-kinase	Homo sapiens	87-91
32332706-5	2020	Further, treatment with the neddylation inhibitor, MLN4924, attenuates high-fat diet-induced hepatic steatosis by reducing the levels of SREBP1c protein and hepatic triglyceride.	pevonedistat	51-58	sterol regulatory element binding transcription factor 1	Mus musculus	137-144
32714568-1	2020	Pevonedistat (MLN4924), a selective inhibitor of the NEDD8-activating enzyme E1 regulatory subunit (NAE1), has demonstrated significant therapeutic potential in several malignancies.	pevonedistat	0-12	NEDD8 activating enzyme E1 subunit 1	Homo sapiens	53-98
32714568-1	2020	Pevonedistat (MLN4924), a selective inhibitor of the NEDD8-activating enzyme E1 regulatory subunit (NAE1), has demonstrated significant therapeutic potential in several malignancies.	pevonedistat	0-12	NEDD8 activating enzyme E1 subunit 1	Homo sapiens	100-104
32714568-1	2020	Pevonedistat (MLN4924), a selective inhibitor of the NEDD8-activating enzyme E1 regulatory subunit (NAE1), has demonstrated significant therapeutic potential in several malignancies.	pevonedistat	14-21	NEDD8 activating enzyme E1 subunit 1	Homo sapiens	53-98
32714568-1	2020	Pevonedistat (MLN4924), a selective inhibitor of the NEDD8-activating enzyme E1 regulatory subunit (NAE1), has demonstrated significant therapeutic potential in several malignancies.	pevonedistat	14-21	NEDD8 activating enzyme E1 subunit 1	Homo sapiens	100-104
32714568-3	2020	In an effort to understand MLN4924-induced cell death in CRC, we identified p53 as an important mediator of the apoptotic response to MLN4924.	pevonedistat	27-34	tumor protein p53	Homo sapiens	76-79
32714568-3	2020	In an effort to understand MLN4924-induced cell death in CRC, we identified p53 as an important mediator of the apoptotic response to MLN4924.	pevonedistat	134-141	tumor protein p53	Homo sapiens	76-79
32714568-4	2020	We also identified roles for the extrinsic (TRAIL-R2/caspase-8) and intrinsic (BAX/BAK) apoptotic pathways in mediating the apoptotic effects of MLN4924 in CRC cells, as well as a role for BID, which modulates a cross-talk between these pathways.	pevonedistat	145-152	caspase 8	Homo sapiens	53-62
32714568-4	2020	We also identified roles for the extrinsic (TRAIL-R2/caspase-8) and intrinsic (BAX/BAK) apoptotic pathways in mediating the apoptotic effects of MLN4924 in CRC cells, as well as a role for BID, which modulates a cross-talk between these pathways.	pevonedistat	145-152	BCL2 associated X, apoptosis regulator	Homo sapiens	79-82
32714568-4	2020	We also identified roles for the extrinsic (TRAIL-R2/caspase-8) and intrinsic (BAX/BAK) apoptotic pathways in mediating the apoptotic effects of MLN4924 in CRC cells, as well as a role for BID, which modulates a cross-talk between these pathways.	pevonedistat	145-152	BCL2 antagonist/killer 1	Homo sapiens	83-86
32714568-4	2020	We also identified roles for the extrinsic (TRAIL-R2/caspase-8) and intrinsic (BAX/BAK) apoptotic pathways in mediating the apoptotic effects of MLN4924 in CRC cells, as well as a role for BID, which modulates a cross-talk between these pathways.	pevonedistat	145-152	BH3 interacting domain death agonist	Homo sapiens	189-192
32714568-5	2020	Depletion of the anti-apoptotic protein FLIP, which we identify as a novel mediator of resistance to MLN4924, enhanced apoptosis in a p53-, TRAIL-R2/DR5-, and caspase-8-dependent manner.	pevonedistat	101-108	tumor protein p53	Homo sapiens	134-137
32714568-5	2020	Depletion of the anti-apoptotic protein FLIP, which we identify as a novel mediator of resistance to MLN4924, enhanced apoptosis in a p53-, TRAIL-R2/DR5-, and caspase-8-dependent manner.	pevonedistat	101-108	TNF receptor superfamily member 10b	Homo sapiens	140-148
32714568-5	2020	Depletion of the anti-apoptotic protein FLIP, which we identify as a novel mediator of resistance to MLN4924, enhanced apoptosis in a p53-, TRAIL-R2/DR5-, and caspase-8-dependent manner.	pevonedistat	101-108	TNF receptor superfamily member 10b	Homo sapiens	149-152
32714568-5	2020	Depletion of the anti-apoptotic protein FLIP, which we identify as a novel mediator of resistance to MLN4924, enhanced apoptosis in a p53-, TRAIL-R2/DR5-, and caspase-8-dependent manner.	pevonedistat	101-108	caspase 8	Homo sapiens	159-168
32714568-6	2020	Notably, TRAIL-R2 was involved in potentiating the apoptotic response to MLN4924 in the absence of FLIP, in a ligand-independent manner.	pevonedistat	73-80	TNF receptor superfamily member 10b	Homo sapiens	9-17
32714568-8	2020	The cell death induced by MLN4924/SN38 combination was dependent on activation of mitochondria through BAX/BAK, but in a p53-independent manner, an important observation given the high frequency of TP53 mutation(s) in advanced CRC.	pevonedistat	26-33	BCL2 associated X, apoptosis regulator	Homo sapiens	103-106
32714568-8	2020	The cell death induced by MLN4924/SN38 combination was dependent on activation of mitochondria through BAX/BAK, but in a p53-independent manner, an important observation given the high frequency of TP53 mutation(s) in advanced CRC.	pevonedistat	26-33	BCL2 antagonist/killer 1	Homo sapiens	107-110
32714568-8	2020	The cell death induced by MLN4924/SN38 combination was dependent on activation of mitochondria through BAX/BAK, but in a p53-independent manner, an important observation given the high frequency of TP53 mutation(s) in advanced CRC.	pevonedistat	26-33	tumor protein p53	Homo sapiens	121-124
32714568-8	2020	The cell death induced by MLN4924/SN38 combination was dependent on activation of mitochondria through BAX/BAK, but in a p53-independent manner, an important observation given the high frequency of TP53 mutation(s) in advanced CRC.	pevonedistat	26-33	tumor protein p53	Homo sapiens	198-202
32360865-0	2020	Nedd8-activating enzyme inhibitor MLN4924 (Pevonedistat), inhibits miR-1303 to suppress human breast cancer cell proliferation via targeting p27Kip1.	pevonedistat	34-41	microRNA 1303	Homo sapiens	67-75
32360865-0	2020	Nedd8-activating enzyme inhibitor MLN4924 (Pevonedistat), inhibits miR-1303 to suppress human breast cancer cell proliferation via targeting p27Kip1.	pevonedistat	34-41	cyclin dependent kinase inhibitor 1B	Homo sapiens	141-148
32360865-0	2020	Nedd8-activating enzyme inhibitor MLN4924 (Pevonedistat), inhibits miR-1303 to suppress human breast cancer cell proliferation via targeting p27Kip1.	pevonedistat	43-55	microRNA 1303	Homo sapiens	67-75
32360865-0	2020	Nedd8-activating enzyme inhibitor MLN4924 (Pevonedistat), inhibits miR-1303 to suppress human breast cancer cell proliferation via targeting p27Kip1.	pevonedistat	43-55	cyclin dependent kinase inhibitor 1B	Homo sapiens	141-148
32360865-1	2020	MLN4924/Pevonedistat, a Nedd8-activating enzyme (NAE, E1) inhibitor, has shown notable anti-cancer effect in pre-clinical trials, but it still faces tolerance resistance risk.	pevonedistat	0-7	NEDD8 ubiquitin like modifier	Homo sapiens	24-29
32360865-1	2020	MLN4924/Pevonedistat, a Nedd8-activating enzyme (NAE, E1) inhibitor, has shown notable anti-cancer effect in pre-clinical trials, but it still faces tolerance resistance risk.	pevonedistat	8-20	NEDD8 ubiquitin like modifier	Homo sapiens	24-29
32360865-4	2020	Here, microRNA-seq analysis showed that the expression of miR-1303 was significantly decreased after MLN4924 treatment in breast cancer cells.	pevonedistat	101-108	microRNA 1303	Homo sapiens	58-66
32360865-9	2020	Notably, excessive miR-1303 partially disturbed the anti-cancer effect of MLN4924.	pevonedistat	74-81	microRNA 1303	Homo sapiens	19-27
32161142-8	2020	Inhibition of Skp2 using the neddylation-activating enzyme (NAE) inhibitor pevonedistat decreased growth of Rb/p53-negative patient-derived cell lines and mouse xenografts.	pevonedistat	75-87	S-phase kinase associated protein 2	Homo sapiens	14-18
32161142-8	2020	Inhibition of Skp2 using the neddylation-activating enzyme (NAE) inhibitor pevonedistat decreased growth of Rb/p53-negative patient-derived cell lines and mouse xenografts.	pevonedistat	75-87	tumor protein p53	Homo sapiens	111-114
32540853-2	2020	It has been noted that MFS and UPS frequently lose function of the tumor suppressor genes RB1 and TP53 In this issue of Cancer Research, Li and colleagues demonstrate that proliferation in RB1- and TP53-deficient MFS and UPS depends on SKP2; inhibiting SKP2 with the neddylation inhibitor, pevonedistat, halts tumor growth in a panel of patient-derived xenografts.	pevonedistat	290-302	RB transcriptional corepressor 1	Homo sapiens	90-93
32540853-2	2020	It has been noted that MFS and UPS frequently lose function of the tumor suppressor genes RB1 and TP53 In this issue of Cancer Research, Li and colleagues demonstrate that proliferation in RB1- and TP53-deficient MFS and UPS depends on SKP2; inhibiting SKP2 with the neddylation inhibitor, pevonedistat, halts tumor growth in a panel of patient-derived xenografts.	pevonedistat	290-302	tumor protein p53	Homo sapiens	98-102
32540853-2	2020	It has been noted that MFS and UPS frequently lose function of the tumor suppressor genes RB1 and TP53 In this issue of Cancer Research, Li and colleagues demonstrate that proliferation in RB1- and TP53-deficient MFS and UPS depends on SKP2; inhibiting SKP2 with the neddylation inhibitor, pevonedistat, halts tumor growth in a panel of patient-derived xenografts.	pevonedistat	290-302	RB transcriptional corepressor 1	Homo sapiens	189-192
32540853-2	2020	It has been noted that MFS and UPS frequently lose function of the tumor suppressor genes RB1 and TP53 In this issue of Cancer Research, Li and colleagues demonstrate that proliferation in RB1- and TP53-deficient MFS and UPS depends on SKP2; inhibiting SKP2 with the neddylation inhibitor, pevonedistat, halts tumor growth in a panel of patient-derived xenografts.	pevonedistat	290-302	S-phase kinase associated protein 2	Homo sapiens	236-240
32540853-2	2020	It has been noted that MFS and UPS frequently lose function of the tumor suppressor genes RB1 and TP53 In this issue of Cancer Research, Li and colleagues demonstrate that proliferation in RB1- and TP53-deficient MFS and UPS depends on SKP2; inhibiting SKP2 with the neddylation inhibitor, pevonedistat, halts tumor growth in a panel of patient-derived xenografts.	pevonedistat	290-302	S-phase kinase associated protein 2	Homo sapiens	253-257
32398095-7	2020	RESULTS: For the first time, we reported that MLN4924, a specific inhibitor of Nedd8-activating enzyme, promoted the expression of ATF3 to induce autophagy in esophageal cancer.	pevonedistat	46-53	NEDD8 ubiquitin like modifier	Homo sapiens	79-84
32398095-7	2020	RESULTS: For the first time, we reported that MLN4924, a specific inhibitor of Nedd8-activating enzyme, promoted the expression of ATF3 to induce autophagy in esophageal cancer.	pevonedistat	46-53	activating transcription factor 3	Homo sapiens	131-135
32398095-8	2020	Mechanistically, MLN4924 inhibited the activity of CRLs and induced the accumulation of its substrate IkappaBalpha to block NF-kappaB activation and Catalase expression.	pevonedistat	17-24	NFKB inhibitor alpha	Homo sapiens	102-114
32398095-8	2020	Mechanistically, MLN4924 inhibited the activity of CRLs and induced the accumulation of its substrate IkappaBalpha to block NF-kappaB activation and Catalase expression.	pevonedistat	17-24	nuclear factor kappa B subunit 1	Homo sapiens	124-133
32398095-8	2020	Mechanistically, MLN4924 inhibited the activity of CRLs and induced the accumulation of its substrate IkappaBalpha to block NF-kappaB activation and Catalase expression.	pevonedistat	17-24	catalase	Homo sapiens	149-157
32398095-9	2020	As a result, MLN4924 activated ATF3-induced protective autophagy, thereby inhibiting MLN4924-induced apoptosis, which could be alleviated by ATF3 silencing.	pevonedistat	13-20	activating transcription factor 3	Homo sapiens	31-35
32398095-9	2020	As a result, MLN4924 activated ATF3-induced protective autophagy, thereby inhibiting MLN4924-induced apoptosis, which could be alleviated by ATF3 silencing.	pevonedistat	13-20	activating transcription factor 3	Homo sapiens	141-145
32398095-9	2020	As a result, MLN4924 activated ATF3-induced protective autophagy, thereby inhibiting MLN4924-induced apoptosis, which could be alleviated by ATF3 silencing.	pevonedistat	85-92	activating transcription factor 3	Homo sapiens	31-35
32398095-10	2020	CONCLUSIONS: In our study, we elucidates a novel mechanism of NF-kappaB/Catalase/ATF3 pathway in MLN4924-induced protective autophagy in esophageal cancer cells, which provides a sound rationale and molecular basis for combinational anti-ESCC therapy with knockdown ATF3 and neddylation inhibitor (e.g. MLN4924).	pevonedistat	97-104	nuclear factor kappa B subunit 1	Homo sapiens	62-71
32398095-10	2020	CONCLUSIONS: In our study, we elucidates a novel mechanism of NF-kappaB/Catalase/ATF3 pathway in MLN4924-induced protective autophagy in esophageal cancer cells, which provides a sound rationale and molecular basis for combinational anti-ESCC therapy with knockdown ATF3 and neddylation inhibitor (e.g. MLN4924).	pevonedistat	97-104	catalase	Homo sapiens	72-80
32398095-10	2020	CONCLUSIONS: In our study, we elucidates a novel mechanism of NF-kappaB/Catalase/ATF3 pathway in MLN4924-induced protective autophagy in esophageal cancer cells, which provides a sound rationale and molecular basis for combinational anti-ESCC therapy with knockdown ATF3 and neddylation inhibitor (e.g. MLN4924).	pevonedistat	97-104	activating transcription factor 3	Homo sapiens	81-85
32398095-10	2020	CONCLUSIONS: In our study, we elucidates a novel mechanism of NF-kappaB/Catalase/ATF3 pathway in MLN4924-induced protective autophagy in esophageal cancer cells, which provides a sound rationale and molecular basis for combinational anti-ESCC therapy with knockdown ATF3 and neddylation inhibitor (e.g. MLN4924).	pevonedistat	97-104	activating transcription factor 3	Homo sapiens	266-270
32398095-10	2020	CONCLUSIONS: In our study, we elucidates a novel mechanism of NF-kappaB/Catalase/ATF3 pathway in MLN4924-induced protective autophagy in esophageal cancer cells, which provides a sound rationale and molecular basis for combinational anti-ESCC therapy with knockdown ATF3 and neddylation inhibitor (e.g. MLN4924).	pevonedistat	303-310	nuclear factor kappa B subunit 1	Homo sapiens	62-71
32398095-10	2020	CONCLUSIONS: In our study, we elucidates a novel mechanism of NF-kappaB/Catalase/ATF3 pathway in MLN4924-induced protective autophagy in esophageal cancer cells, which provides a sound rationale and molecular basis for combinational anti-ESCC therapy with knockdown ATF3 and neddylation inhibitor (e.g. MLN4924).	pevonedistat	303-310	catalase	Homo sapiens	72-80
32398095-10	2020	CONCLUSIONS: In our study, we elucidates a novel mechanism of NF-kappaB/Catalase/ATF3 pathway in MLN4924-induced protective autophagy in esophageal cancer cells, which provides a sound rationale and molecular basis for combinational anti-ESCC therapy with knockdown ATF3 and neddylation inhibitor (e.g. MLN4924).	pevonedistat	303-310	activating transcription factor 3	Homo sapiens	81-85
32008742-5	2020	Consistent with this, treatment with MLN4924, a Cullin-neddylation inhibitor that suppresses SCF E3 activity, increased Lipin-2 protein and concomitantly decreased Il1b expression.	pevonedistat	37-44	lipin 2	Homo sapiens	120-127
32008742-5	2020	Consistent with this, treatment with MLN4924, a Cullin-neddylation inhibitor that suppresses SCF E3 activity, increased Lipin-2 protein and concomitantly decreased Il1b expression.	pevonedistat	37-44	interleukin 1 beta	Homo sapiens	164-168
32145689-6	2020	Mechanistically, MLN4924 repressed the transcription of AR/AR-V7 and its downstream targets, and blocked MMP2 and MMP9 expression.	pevonedistat	17-24	androgen receptor	Homo sapiens	56-58
32145689-6	2020	Mechanistically, MLN4924 repressed the transcription of AR/AR-V7 and its downstream targets, and blocked MMP2 and MMP9 expression.	pevonedistat	17-24	matrix metallopeptidase 2	Homo sapiens	105-109
32145689-6	2020	Mechanistically, MLN4924 repressed the transcription of AR/AR-V7 and its downstream targets, and blocked MMP2 and MMP9 expression.	pevonedistat	17-24	matrix metallopeptidase 9	Homo sapiens	114-118
33073261-0	2020	Pevonedistat, a NEDD8-Activating Enzyme Inhibitor, Induces Apoptosis and Augments Efficacy of Chemotherapy and Small Molecule Inhibitors in Pre-clinical Models of Diffuse Large B-cell Lymphoma.	pevonedistat	0-12	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	16-21
33073261-1	2020	We studied the biological activity of pevonedistat, a first-in-class NEDD8-activating enzyme (NAE) inhibitor, in combination with various cytotoxic chemotherapy agents and small molecule inhibitors in lymphoma pre-clinical models.	pevonedistat	38-50	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	69-74
31705877-5	2020	We observed that cSCC cells can be selectively killed by small-molecule inhibitors of USP8 (DUBs-IN-3/compound 22c) and the NEDD8 E1 activating enzyme/CRLs (MLN4924/pevonedistat).	pevonedistat	157-164	NEDD8 ubiquitin like modifier	Homo sapiens	124-129
32466489-8	2020	The CRBN-targeting immunomodulatory drug lenalidomide and the cullin E3 ligase inhibitor MLN4924 promotes and attenuates, respectively, proteasomal degradation of ClC-2.	pevonedistat	89-96	cereblon	Homo sapiens	4-8
32466489-8	2020	The CRBN-targeting immunomodulatory drug lenalidomide and the cullin E3 ligase inhibitor MLN4924 promotes and attenuates, respectively, proteasomal degradation of ClC-2.	pevonedistat	89-96	CDK2 associated cullin domain 1	Homo sapiens	62-68
32466489-8	2020	The CRBN-targeting immunomodulatory drug lenalidomide and the cullin E3 ligase inhibitor MLN4924 promotes and attenuates, respectively, proteasomal degradation of ClC-2.	pevonedistat	89-96	chloride voltage-gated channel 2	Homo sapiens	163-168
32266102-2	2020	MLN4924, a small molecule of NEDD8-activating enzyme inhibitor, inactivates CRL by blocking cullin neddylation and has been reported to elicit anti-tumor effect.	pevonedistat	0-7	interleukin 31 receptor A	Homo sapiens	76-79
32109374-4	2020	Blockade of this Nedd8 clearance pathway with MLN4924 causes accumulation of misfolded protein aggregates, ultimately inducing immunogenic cell death in dMMR cancer cells.	pevonedistat	46-53	NEDD8 ubiquitin like modifier	Homo sapiens	17-22
31857349-6	2020	Furthermore, based on the downstream actions of these genes, we evaluated the activity of proteasome inhibitors as well as the specific NEDD8-activating enzyme inhibitor, MLN4924 (Pevonedistat), in AC sensitization.	pevonedistat	171-178	NEDD8 ubiquitin like modifier	Homo sapiens	136-141
31857349-6	2020	Furthermore, based on the downstream actions of these genes, we evaluated the activity of proteasome inhibitors as well as the specific NEDD8-activating enzyme inhibitor, MLN4924 (Pevonedistat), in AC sensitization.	pevonedistat	180-192	NEDD8 ubiquitin like modifier	Homo sapiens	136-141
32059437-1	2020	MLN4924 (pevonedistat) is a first-in-class NEDD8-activating enzyme (NAE) inhibitor in clinical trials for the treatment of solid tumors and hematologic malignancies.	pevonedistat	0-7	NEDD8 ubiquitin like modifier	Homo sapiens	43-48
32059437-10	2020	Importantly, the sensitivity of MLN4924-resistant cells was restored by lentiviral short hairpin RNA (shRNA) targeting ABCG2.	pevonedistat	32-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	119-124
32059437-11	2020	Further investigation using ABCG2-overexpressing NCI-H460/MX20 cells determined that these cells are resistant to the anticancer effects of MLN4924 and can be sensitized by co-treatment with the ABCG2 inhibitors YHO-13351 and fumitremorgin C.	pevonedistat	140-147	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	28-33
32059437-11	2020	Further investigation using ABCG2-overexpressing NCI-H460/MX20 cells determined that these cells are resistant to the anticancer effects of MLN4924 and can be sensitized by co-treatment with the ABCG2 inhibitors YHO-13351 and fumitremorgin C.	pevonedistat	140-147	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	195-200
32059437-12	2020	Finally, HEK293 models with overexpression of wild-type ABCG2 (R482) and variants (R482G and R482T) all demonstrated significant resistance to MLN4924 compared to wild-type cells.	pevonedistat	143-150	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	56-61
32059437-13	2020	Overall, these findings define an important molecular resistance mechanism to MLN4924 and demonstrate that ABCG2 may be a useful clinical biomarker that predicts resistance to MLN4924 treatment.	pevonedistat	78-85	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	107-112
32059437-13	2020	Overall, these findings define an important molecular resistance mechanism to MLN4924 and demonstrate that ABCG2 may be a useful clinical biomarker that predicts resistance to MLN4924 treatment.	pevonedistat	176-183	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	107-112
32266102-2	2020	MLN4924, a small molecule of NEDD8-activating enzyme inhibitor, inactivates CRL by blocking cullin neddylation and has been reported to elicit anti-tumor effect.	pevonedistat	0-7	CDK2 associated cullin domain 1	Homo sapiens	92-98
32266102-5	2020	MLN4924 inhibits proliferation and interferes with the cell cycle checkpoint regulators, p21, p27, and phospho-histone H3.	pevonedistat	0-7	H3 histone pseudogene 16	Homo sapiens	89-92
32266102-5	2020	MLN4924 inhibits proliferation and interferes with the cell cycle checkpoint regulators, p21, p27, and phospho-histone H3.	pevonedistat	0-7	dynactin subunit 6	Homo sapiens	94-97
32266102-7	2020	MLN4924 decreased VEGF-activated cell proliferation via neddylation inhibition.	pevonedistat	0-7	vascular endothelial growth factor A	Homo sapiens	18-22
32266102-8	2020	MLN4924 inhibited VEGF-activated cell migration, capillary tube formation and VEGF-mediated Erk1/2 activation in HUVECs.	pevonedistat	0-7	vascular endothelial growth factor A	Homo sapiens	18-22
32266102-8	2020	MLN4924 inhibited VEGF-activated cell migration, capillary tube formation and VEGF-mediated Erk1/2 activation in HUVECs.	pevonedistat	0-7	vascular endothelial growth factor A	Homo sapiens	78-82
32266102-8	2020	MLN4924 inhibited VEGF-activated cell migration, capillary tube formation and VEGF-mediated Erk1/2 activation in HUVECs.	pevonedistat	0-7	mitogen-activated protein kinase 3	Homo sapiens	92-98
32266102-10	2020	The in vivo results showed MLN4924 inhibited tumor growth in all four types of cancers with decreasing CD31 expression in xenograft tumor.	pevonedistat	27-34	platelet and endothelial cell adhesion molecule 1	Homo sapiens	103-107
32266102-11	2020	In conclusion, MLN4924 inhibited viability, migration, and VEGF-promoted angiogenic activity in HUVECs; consistently, MLN4924 inhibited tumor growth in four types of cancers with suppression of angiogenesis.	pevonedistat	15-22	vascular endothelial growth factor A	Homo sapiens	59-63
32123578-6	2020	Here, we show that the NAE inhibitor, Pevonedistat (MLN4924), potently inhibits RB1 null and MYCN amp tumors.	pevonedistat	38-50	RB transcriptional corepressor 1	Homo sapiens	80-83
32015554-4	2020	Using sNUSP, we identified 607 neddylation sites dynamically regulated by the neddylation inhibitor MLN4924 and the de-neddylating enzyme NEDP1, implying that many non-cullin proteins are neddylated.	pevonedistat	100-107	CDK2 associated cullin domain 1	Homo sapiens	168-174
32123578-6	2020	Here, we show that the NAE inhibitor, Pevonedistat (MLN4924), potently inhibits RB1 null and MYCN amp tumors.	pevonedistat	38-50	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	93-97
31898235-4	2020	The process of protein neddylation is overactivated in multiple types of human cancers, providing a sound rationale as an attractive anticancer therapeutic strategy, evidenced by the development of the NEDD8-activating enzyme (NAE) inhibitor MLN4924 (also known as pevonedistat).	pevonedistat	242-249	NEDD8 ubiquitin like modifier	Homo sapiens	202-207
31898235-4	2020	The process of protein neddylation is overactivated in multiple types of human cancers, providing a sound rationale as an attractive anticancer therapeutic strategy, evidenced by the development of the NEDD8-activating enzyme (NAE) inhibitor MLN4924 (also known as pevonedistat).	pevonedistat	265-277	NEDD8 ubiquitin like modifier	Homo sapiens	202-207
31898238-7	2020	And finally, MLN4924 activates the JNK signaling pathway to reduce c-FLIP levels, thus enhancing TRAIL-induced apoptosis.	pevonedistat	13-20	CASP8 and FADD like apoptosis regulator	Homo sapiens	67-73
31898237-6	2020	MLN4924 is currently in the Phase I/II clinical trials for anticancer application.In the last few years, targeting protein-protein interactions of the neddylation complexes has been pursued as a potential strategy to selectively inhibit the activity of individual CRL.	pevonedistat	0-7	interleukin 31 receptor A	Homo sapiens	264-267
31898238-7	2020	And finally, MLN4924 activates the JNK signaling pathway to reduce c-FLIP levels, thus enhancing TRAIL-induced apoptosis.	pevonedistat	13-20	TNF superfamily member 10	Homo sapiens	97-102
31898238-1	2020	MLN4924, also known as pevonedistat, is a highly selective small-molecule inhibitor of NEDD8 (neuronal precursor cell-expressed developmentally downregulated protein 8)-activating enzyme (NAE) to block the entire neddylation modification cascade, leading to inactivation of cullin-RING ligases (CRLs), since activation of CRLs requires cullin neddylation.	pevonedistat	0-7	NEDD8 ubiquitin like modifier	Homo sapiens	87-92
31898238-1	2020	MLN4924, also known as pevonedistat, is a highly selective small-molecule inhibitor of NEDD8 (neuronal precursor cell-expressed developmentally downregulated protein 8)-activating enzyme (NAE) to block the entire neddylation modification cascade, leading to inactivation of cullin-RING ligases (CRLs), since activation of CRLs requires cullin neddylation.	pevonedistat	0-7	NEDD8 ubiquitin like modifier	Homo sapiens	94-167
31898238-1	2020	MLN4924, also known as pevonedistat, is a highly selective small-molecule inhibitor of NEDD8 (neuronal precursor cell-expressed developmentally downregulated protein 8)-activating enzyme (NAE) to block the entire neddylation modification cascade, leading to inactivation of cullin-RING ligases (CRLs), since activation of CRLs requires cullin neddylation.	pevonedistat	0-7	CDK2 associated cullin domain 1	Homo sapiens	274-280
31898238-1	2020	MLN4924, also known as pevonedistat, is a highly selective small-molecule inhibitor of NEDD8 (neuronal precursor cell-expressed developmentally downregulated protein 8)-activating enzyme (NAE) to block the entire neddylation modification cascade, leading to inactivation of cullin-RING ligases (CRLs), since activation of CRLs requires cullin neddylation.	pevonedistat	0-7	CDK2 associated cullin domain 1	Homo sapiens	336-342
31898238-1	2020	MLN4924, also known as pevonedistat, is a highly selective small-molecule inhibitor of NEDD8 (neuronal precursor cell-expressed developmentally downregulated protein 8)-activating enzyme (NAE) to block the entire neddylation modification cascade, leading to inactivation of cullin-RING ligases (CRLs), since activation of CRLs requires cullin neddylation.	pevonedistat	23-35	NEDD8 ubiquitin like modifier	Homo sapiens	87-92
31898238-1	2020	MLN4924, also known as pevonedistat, is a highly selective small-molecule inhibitor of NEDD8 (neuronal precursor cell-expressed developmentally downregulated protein 8)-activating enzyme (NAE) to block the entire neddylation modification cascade, leading to inactivation of cullin-RING ligases (CRLs), since activation of CRLs requires cullin neddylation.	pevonedistat	23-35	NEDD8 ubiquitin like modifier	Homo sapiens	94-167
31898238-1	2020	MLN4924, also known as pevonedistat, is a highly selective small-molecule inhibitor of NEDD8 (neuronal precursor cell-expressed developmentally downregulated protein 8)-activating enzyme (NAE) to block the entire neddylation modification cascade, leading to inactivation of cullin-RING ligases (CRLs), since activation of CRLs requires cullin neddylation.	pevonedistat	23-35	CDK2 associated cullin domain 1	Homo sapiens	274-280
31898238-1	2020	MLN4924, also known as pevonedistat, is a highly selective small-molecule inhibitor of NEDD8 (neuronal precursor cell-expressed developmentally downregulated protein 8)-activating enzyme (NAE) to block the entire neddylation modification cascade, leading to inactivation of cullin-RING ligases (CRLs), since activation of CRLs requires cullin neddylation.	pevonedistat	23-35	CDK2 associated cullin domain 1	Homo sapiens	336-342
31898238-3	2020	First, MLN4924 triggers EGFR dimerization to activate EGFR and its downstream RAS/MAPK and PI3K/AKT1 signals, leading to enhanced tumor sphere formation, accelerated EGF-mediated wound healing, and inhibited ciliogenesis.	pevonedistat	7-14	epidermal growth factor receptor	Homo sapiens	24-28
31898238-3	2020	First, MLN4924 triggers EGFR dimerization to activate EGFR and its downstream RAS/MAPK and PI3K/AKT1 signals, leading to enhanced tumor sphere formation, accelerated EGF-mediated wound healing, and inhibited ciliogenesis.	pevonedistat	7-14	epidermal growth factor receptor	Homo sapiens	54-58
31898238-3	2020	First, MLN4924 triggers EGFR dimerization to activate EGFR and its downstream RAS/MAPK and PI3K/AKT1 signals, leading to enhanced tumor sphere formation, accelerated EGF-mediated wound healing, and inhibited ciliogenesis.	pevonedistat	7-14	AKT serine/threonine kinase 1	Homo sapiens	96-100
31898238-4	2020	Second, MLN4924 induces PKM2 tetramerization to promote glycolysis, thus affecting energy metabolism.	pevonedistat	8-15	pyruvate kinase M1/2	Homo sapiens	24-28
31898238-5	2020	Third, MLN4924 inhibits the interaction between ACT1 (NF-kappaB activator 1) and TRAF6 (tumor necrosis factor receptor-associated factor 6) and attenuates IL-17A-mediated activation of NF-kappaB to reduce pulmonary inflammation.	pevonedistat	7-14	TRAF3 interacting protein 2	Homo sapiens	48-52
31898238-5	2020	Third, MLN4924 inhibits the interaction between ACT1 (NF-kappaB activator 1) and TRAF6 (tumor necrosis factor receptor-associated factor 6) and attenuates IL-17A-mediated activation of NF-kappaB to reduce pulmonary inflammation.	pevonedistat	7-14	TNF receptor associated factor 6	Homo sapiens	81-86
31898238-5	2020	Third, MLN4924 inhibits the interaction between ACT1 (NF-kappaB activator 1) and TRAF6 (tumor necrosis factor receptor-associated factor 6) and attenuates IL-17A-mediated activation of NF-kappaB to reduce pulmonary inflammation.	pevonedistat	7-14	TNF receptor associated factor 6	Homo sapiens	88-138
31898238-5	2020	Third, MLN4924 inhibits the interaction between ACT1 (NF-kappaB activator 1) and TRAF6 (tumor necrosis factor receptor-associated factor 6) and attenuates IL-17A-mediated activation of NF-kappaB to reduce pulmonary inflammation.	pevonedistat	7-14	interleukin 17A	Homo sapiens	155-161
31898238-5	2020	Third, MLN4924 inhibits the interaction between ACT1 (NF-kappaB activator 1) and TRAF6 (tumor necrosis factor receptor-associated factor 6) and attenuates IL-17A-mediated activation of NF-kappaB to reduce pulmonary inflammation.	pevonedistat	7-14	nuclear factor kappa B subunit 1	Homo sapiens	54-63
31898238-6	2020	Fourth, MLN4924 inhibits IRF3 binding to the IFN-beta promoter to inhibit IFN-beta production.	pevonedistat	8-15	interferon regulatory factor 3	Homo sapiens	25-29
31898238-6	2020	Fourth, MLN4924 inhibits IRF3 binding to the IFN-beta promoter to inhibit IFN-beta production.	pevonedistat	8-15	IFN1@	Homo sapiens	45-53
31898238-6	2020	Fourth, MLN4924 inhibits IRF3 binding to the IFN-beta promoter to inhibit IFN-beta production.	pevonedistat	8-15	IFN1@	Homo sapiens	74-82
31898238-7	2020	And finally, MLN4924 activates the JNK signaling pathway to reduce c-FLIP levels, thus enhancing TRAIL-induced apoptosis.	pevonedistat	13-20	mitogen-activated protein kinase 8	Homo sapiens	35-38
31771104-0	2019	The Protein Neddylation Inhibitor MLN4924 Suppresses Patient-Derived Glioblastoma Cells via Inhibition of ERK and AKT Signaling.	pevonedistat	34-41	mitogen-activated protein kinase 1	Homo sapiens	106-109
32579500-8	2020	Moreover, using MLN4924 (APP-BP1 pathway blocker), we also verified the components of the downstream effector cascade of the APP-BP1 pathway, including tau, APP-cleaving secretases, beta-catenin and p53.	pevonedistat	16-23	NEDD8 activating enzyme E1 subunit 1	Homo sapiens	25-32
32579500-8	2020	Moreover, using MLN4924 (APP-BP1 pathway blocker), we also verified the components of the downstream effector cascade of the APP-BP1 pathway, including tau, APP-cleaving secretases, beta-catenin and p53.	pevonedistat	16-23	NEDD8 activating enzyme E1 subunit 1	Homo sapiens	125-132
31771104-0	2019	The Protein Neddylation Inhibitor MLN4924 Suppresses Patient-Derived Glioblastoma Cells via Inhibition of ERK and AKT Signaling.	pevonedistat	34-41	AKT serine/threonine kinase 1	Homo sapiens	114-117
31771104-2	2019	Abnormal activation of the neddylation pathway is observed in glioblastoma, and the NEDD8-activating enzyme (NAE) inhibitor, MLN4924, was previously shown to be effective in glioblastoma cell line models.	pevonedistat	125-132	NEDD8 ubiquitin like modifier	Homo sapiens	84-89
31771104-10	2019	Genomic analyses indicated that MLN4924 sensitive cells exhibited enrichment of Extracellular Signal Regulated Kinase (ERK) and Protein kinase B (AKT, also known as PKB) signaling.	pevonedistat	32-39	mitogen-activated protein kinase 1	Homo sapiens	80-117
31771104-10	2019	Genomic analyses indicated that MLN4924 sensitive cells exhibited enrichment of Extracellular Signal Regulated Kinase (ERK) and Protein kinase B (AKT, also known as PKB) signaling.	pevonedistat	32-39	mitogen-activated protein kinase 1	Homo sapiens	119-122
31771104-10	2019	Genomic analyses indicated that MLN4924 sensitive cells exhibited enrichment of Extracellular Signal Regulated Kinase (ERK) and Protein kinase B (AKT, also known as PKB) signaling.	pevonedistat	32-39	AKT serine/threonine kinase 1	Homo sapiens	146-149
31771104-10	2019	Genomic analyses indicated that MLN4924 sensitive cells exhibited enrichment of Extracellular Signal Regulated Kinase (ERK) and Protein kinase B (AKT, also known as PKB) signaling.	pevonedistat	32-39	AKT serine/threonine kinase 1	Homo sapiens	165-168
31771104-11	2019	We verified that MLN4924 inhibits ERK and AKT phosphorylation in MLN4924 sensitive cells.	pevonedistat	17-24	mitogen-activated protein kinase 1	Homo sapiens	34-37
31771104-11	2019	We verified that MLN4924 inhibits ERK and AKT phosphorylation in MLN4924 sensitive cells.	pevonedistat	17-24	AKT serine/threonine kinase 1	Homo sapiens	42-45
31771104-11	2019	We verified that MLN4924 inhibits ERK and AKT phosphorylation in MLN4924 sensitive cells.	pevonedistat	65-72	mitogen-activated protein kinase 1	Homo sapiens	34-37
31771104-11	2019	We verified that MLN4924 inhibits ERK and AKT phosphorylation in MLN4924 sensitive cells.	pevonedistat	65-72	AKT serine/threonine kinase 1	Homo sapiens	42-45
31301771-8	2019	The Nedd8-activating enzyme inhibitor MLN4924 decreased E4orf6-induced neddylation of the cullin5 protein and subsequently suppressed p53 degradation.	pevonedistat	38-45	tumor protein p53	Homo sapiens	134-137
31548378-3	2019	Here we report that MLN4924, also known as pevonedistat, a small-molecule inhibitor of neddylation currently in phase II clinical trials, down-regulates SOX2 expression via causing accumulation of MSX2, a known transcription repressor of SOX2 expression.	pevonedistat	20-27	SRY-box transcription factor 2	Homo sapiens	153-157
31548378-3	2019	Here we report that MLN4924, also known as pevonedistat, a small-molecule inhibitor of neddylation currently in phase II clinical trials, down-regulates SOX2 expression via causing accumulation of MSX2, a known transcription repressor of SOX2 expression.	pevonedistat	20-27	msh homeobox 2	Homo sapiens	197-201
31548378-3	2019	Here we report that MLN4924, also known as pevonedistat, a small-molecule inhibitor of neddylation currently in phase II clinical trials, down-regulates SOX2 expression via causing accumulation of MSX2, a known transcription repressor of SOX2 expression.	pevonedistat	20-27	SRY-box transcription factor 2	Homo sapiens	238-242
31548378-3	2019	Here we report that MLN4924, also known as pevonedistat, a small-molecule inhibitor of neddylation currently in phase II clinical trials, down-regulates SOX2 expression via causing accumulation of MSX2, a known transcription repressor of SOX2 expression.	pevonedistat	43-55	SRY-box transcription factor 2	Homo sapiens	153-157
31548378-3	2019	Here we report that MLN4924, also known as pevonedistat, a small-molecule inhibitor of neddylation currently in phase II clinical trials, down-regulates SOX2 expression via causing accumulation of MSX2, a known transcription repressor of SOX2 expression.	pevonedistat	43-55	msh homeobox 2	Homo sapiens	197-201
31548378-3	2019	Here we report that MLN4924, also known as pevonedistat, a small-molecule inhibitor of neddylation currently in phase II clinical trials, down-regulates SOX2 expression via causing accumulation of MSX2, a known transcription repressor of SOX2 expression.	pevonedistat	43-55	SRY-box transcription factor 2	Homo sapiens	238-242
31548378-9	2019	By down-regulating SOX2 through inactivation of FBXW2 E3 ligase, MLN4924 sensitizes breast cancer cells to tamoxifen in both in vitro and in vivo cancer cell models.	pevonedistat	65-72	SRY-box transcription factor 2	Homo sapiens	19-23
31548378-9	2019	By down-regulating SOX2 through inactivation of FBXW2 E3 ligase, MLN4924 sensitizes breast cancer cells to tamoxifen in both in vitro and in vivo cancer cell models.	pevonedistat	65-72	F-box and WD repeat domain containing 2	Homo sapiens	48-53
31548378-13	2019	By inactivating FBXW2, MLN4924 caused MSX2 accumulation to repress SOX2 expression, leading to suppression of stem cell property and sensitization of breast cancer cells to tamoxifen.	pevonedistat	23-30	F-box and WD repeat domain containing 2	Homo sapiens	16-21
31548378-13	2019	By inactivating FBXW2, MLN4924 caused MSX2 accumulation to repress SOX2 expression, leading to suppression of stem cell property and sensitization of breast cancer cells to tamoxifen.	pevonedistat	23-30	msh homeobox 2	Homo sapiens	38-42
31548378-13	2019	By inactivating FBXW2, MLN4924 caused MSX2 accumulation to repress SOX2 expression, leading to suppression of stem cell property and sensitization of breast cancer cells to tamoxifen.	pevonedistat	23-30	SRY-box transcription factor 2	Homo sapiens	67-71
31406256-8	2019	Inhibition of CRL activity, by either NEDD8/RBX1 silencing or pevonedistat treatment of cells resulted in induction of apoptosis that could be partially rescued by siRNA-based silencing of p27.	pevonedistat	62-74	interleukin 31 receptor A	Homo sapiens	14-17
31511500-0	2019	Correction: Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication.	pevonedistat	115-127	NEDD8 ubiquitin like modifier	Homo sapiens	81-86
31349760-0	2019	The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.	pevonedistat	38-45	NEDD8 ubiquitin like modifier	Homo sapiens	4-9
31216194-9	2019	Consistent with this, Cullin-3 inhibition with MLN4924 is sufficient to reduce migration of normal fibroblasts.	pevonedistat	47-54	cullin 3	Mus musculus	22-30
31349760-0	2019	The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.	pevonedistat	38-45	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	100-103
31002342-5	2019	Inhibition of neddylation by MLN4924, a small-molecule inhibitor of NAE1, significantly inhibited HCC growth, reduced clonogenic survival, increased apoptosis, and decreased migration capacity.	pevonedistat	29-36	NEDD8 activating enzyme E1 subunit 1	Homo sapiens	68-72
31406107-0	2019	The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1+ subgroup of multiple myeloma cells for TNF-induced cell death.	pevonedistat	38-45	TNF receptor superfamily member 1A	Homo sapiens	59-64
31406107-0	2019	The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1+ subgroup of multiple myeloma cells for TNF-induced cell death.	pevonedistat	38-45	tumor necrosis factor	Homo sapiens	59-62
31406107-1	2019	The NEDD8-activating enzyme (NAE) inhibitor MLN4924 inhibits cullin-RING ubiquitin ligase complexes including the SKP1-cullin-F-box E3 ligase betaTrCP.	pevonedistat	44-51	beta-transducin repeat containing E3 ubiquitin protein ligase	Homo sapiens	142-150
31044422-5	2019	Consistently, neddylation inhibitor pevonedistat significantly enhances PD-L1 expression in both glioblastoma cancer cell lines and animal models.	pevonedistat	36-48	CD274 molecule	Homo sapiens	72-77
31044422-6	2019	Mechanistically, pevonedistat increases PD-L1 mRNA levels mainly through inhibiting Cullin1-F-box and WD repeat domain-containing 7 E3 ligase activity and accumulating c-MYC proteins, a direct transcriptional activator of PD-L1 gene expression.	pevonedistat	17-29	CD274 molecule	Homo sapiens	40-45
31044422-6	2019	Mechanistically, pevonedistat increases PD-L1 mRNA levels mainly through inhibiting Cullin1-F-box and WD repeat domain-containing 7 E3 ligase activity and accumulating c-MYC proteins, a direct transcriptional activator of PD-L1 gene expression.	pevonedistat	17-29	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	168-173
31044422-6	2019	Mechanistically, pevonedistat increases PD-L1 mRNA levels mainly through inhibiting Cullin1-F-box and WD repeat domain-containing 7 E3 ligase activity and accumulating c-MYC proteins, a direct transcriptional activator of PD-L1 gene expression.	pevonedistat	17-29	CD274 molecule	Homo sapiens	222-227
31044422-8	2019	Importantly, pevonedistat attenuates T cell killing through PD-L1 induction, and blockade of PD-L1 restores the sensitivity of pevonedistat-treated glioblastoma cancer cells to T cell killing.	pevonedistat	13-25	CD274 molecule	Homo sapiens	60-65
31044422-8	2019	Importantly, pevonedistat attenuates T cell killing through PD-L1 induction, and blockade of PD-L1 restores the sensitivity of pevonedistat-treated glioblastoma cancer cells to T cell killing.	pevonedistat	127-139	CD274 molecule	Homo sapiens	93-98
30845347-0	2019	Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.	pevonedistat	54-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	10-15
30833270-4	2019	ER-alpha expression was investigated using animal 18F-FES-PET/CT and immunoblotting upon NAE inhibitor MLN4924 treatment.	pevonedistat	103-110	estrogen receptor 1	Homo sapiens	0-8
30833270-5	2019	Chromatin immunoprecipitation assay, luciferase reporter promoter assay, and the CRISPR-Cas9 system were used to elucidate the mechanism of ER-alpha regulation by MLN4924.	pevonedistat	163-170	estrogen receptor 1	Homo sapiens	140-148
30833270-10	2019	Importantly, ER-alpha expression was significantly downregulated upon MLN4924 treatment in vitro and in vivo.	pevonedistat	70-77	estrogen receptor 1	Homo sapiens	13-21
30833270-11	2019	Mechanistically, MLN4924 treatment delayed serum and glucocorticoid-induced protein kinase (SGK) degradation and induced Forkhead box O3a (FOXO3a) nuclear export as well as decreased binding to the ESR1 promoter.	pevonedistat	17-24	forkhead box O3	Homo sapiens	121-137
30833270-11	2019	Mechanistically, MLN4924 treatment delayed serum and glucocorticoid-induced protein kinase (SGK) degradation and induced Forkhead box O3a (FOXO3a) nuclear export as well as decreased binding to the ESR1 promoter.	pevonedistat	17-24	forkhead box O3	Homo sapiens	139-145
30833270-11	2019	Mechanistically, MLN4924 treatment delayed serum and glucocorticoid-induced protein kinase (SGK) degradation and induced Forkhead box O3a (FOXO3a) nuclear export as well as decreased binding to the ESR1 promoter.	pevonedistat	17-24	estrogen receptor 1	Homo sapiens	198-202
30892082-0	2019	MLN4924 protects against interleukin-17A-induced pulmonary inflammation by disrupting ACT1-mediated signaling.	pevonedistat	0-7	interleukin 17A	Mus musculus	25-40
30892082-0	2019	MLN4924 protects against interleukin-17A-induced pulmonary inflammation by disrupting ACT1-mediated signaling.	pevonedistat	0-7	actin related gene 1	Mus musculus	86-90
30892082-3	2019	MLN4924, an inhibitor of NEDD8-activating enzyme (NAE), is associated with the treatment of various types of cancers, but its role in the IL-17A-mediated inflammatory response has not been identified.	pevonedistat	0-7	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	25-30
30892082-3	2019	MLN4924, an inhibitor of NEDD8-activating enzyme (NAE), is associated with the treatment of various types of cancers, but its role in the IL-17A-mediated inflammatory response has not been identified.	pevonedistat	0-7	interleukin 17A	Mus musculus	138-144
30892082-4	2019	Here, we report that MLN4924 can markedly reduce the expression of proinflammatory cytokines and chemokines such as IL-1beta, IL-6, and CXCL-1 and neutrophilia in a mouse model of IL-17A adenovirus-induced pulmonary inflammation.	pevonedistat	21-28	interleukin 1 alpha	Mus musculus	116-124
30892082-4	2019	Here, we report that MLN4924 can markedly reduce the expression of proinflammatory cytokines and chemokines such as IL-1beta, IL-6, and CXCL-1 and neutrophilia in a mouse model of IL-17A adenovirus-induced pulmonary inflammation.	pevonedistat	21-28	interleukin 6	Mus musculus	126-130
30892082-4	2019	Here, we report that MLN4924 can markedly reduce the expression of proinflammatory cytokines and chemokines such as IL-1beta, IL-6, and CXCL-1 and neutrophilia in a mouse model of IL-17A adenovirus-induced pulmonary inflammation.	pevonedistat	21-28	chemokine (C-X-C motif) ligand 1	Mus musculus	136-142
30892082-4	2019	Here, we report that MLN4924 can markedly reduce the expression of proinflammatory cytokines and chemokines such as IL-1beta, IL-6, and CXCL-1 and neutrophilia in a mouse model of IL-17A adenovirus-induced pulmonary inflammation.	pevonedistat	21-28	interleukin 17A	Mus musculus	180-186
30892082-5	2019	MLN4924 significantly inhibited IL-17A-induced stabilization of mRNA of proinflammatory cytokines and chemokines in vitro.	pevonedistat	0-7	interleukin 17A	Mus musculus	32-38
30892082-6	2019	Mechanistically, MLN4924 significantly blocked the activation of MAPK and NF-kappaB pathways and interfered with the interaction between ACT1 and tumor necrosis factor receptor-associated factor proteins (TRAFs), thereby inhibiting TRAF6 ubiquitination.	pevonedistat	17-24	actin related gene 1	Mus musculus	137-141
30892082-6	2019	Mechanistically, MLN4924 significantly blocked the activation of MAPK and NF-kappaB pathways and interfered with the interaction between ACT1 and tumor necrosis factor receptor-associated factor proteins (TRAFs), thereby inhibiting TRAF6 ubiquitination.	pevonedistat	17-24	TNF receptor-associated factor 6	Mus musculus	232-237
30892082-7	2019	Taken together, our data uncover a previously uncharacterized inhibitory effect of MLN4924 on the IL-17A-mediated inflammatory response; this phenomenon may facilitate the development of MLN4924 into an effective small-molecule drug for the treatment of pulmonary inflammatory diseases.	pevonedistat	83-90	interleukin 17A	Mus musculus	98-104
30892082-7	2019	Taken together, our data uncover a previously uncharacterized inhibitory effect of MLN4924 on the IL-17A-mediated inflammatory response; this phenomenon may facilitate the development of MLN4924 into an effective small-molecule drug for the treatment of pulmonary inflammatory diseases.	pevonedistat	187-194	interleukin 17A	Mus musculus	98-104
30850948-0	2019	Neddylation inhibitor MLN4924 suppresses cilia formation by modulating AKT1.	pevonedistat	22-29	AKT serine/threonine kinase 1	Homo sapiens	71-75
31057046-3	2019	Previously, inhibition of CRL neddylation by MLN4924, a small molecule inhibitor of the NEDD8-activating enzyme 1 (NAE1), was shown to induce interphase cell cycle arrest and cell death.	pevonedistat	45-52	interleukin 31 receptor A	Homo sapiens	26-29
31148579-4	2019	Previously we showed that inhibition of Cullin RING ligase activity by the neddylation inhibitor MLN4924 is detrimental for endothelial barrier function, due to accumulation of RhoB and the consequent induction of contractility.	pevonedistat	97-104	ras homolog family member B	Homo sapiens	177-181
30586159-5	2019	Here, we show that pevonedistat, a NEDD8-activating enzyme inhibitor, works efficiently as an antiviral agent.	pevonedistat	19-31	NEDD8 ubiquitin like modifier	Homo sapiens	35-40
30586159-6	2019	Pevonedistat significantly restored Smc5/6 protein levels and suppressed viral transcription and protein production in the HBV minicircle system in in vitro HBV replication models and in human primary hepatocytes infected naturally with HBV.	pevonedistat	0-12	structural maintenance of chromosomes 5	Homo sapiens	36-42
31057046-3	2019	Previously, inhibition of CRL neddylation by MLN4924, a small molecule inhibitor of the NEDD8-activating enzyme 1 (NAE1), was shown to induce interphase cell cycle arrest and cell death.	pevonedistat	45-52	NEDD8 activating enzyme E1 subunit 1	Homo sapiens	88-113
31057046-3	2019	Previously, inhibition of CRL neddylation by MLN4924, a small molecule inhibitor of the NEDD8-activating enzyme 1 (NAE1), was shown to induce interphase cell cycle arrest and cell death.	pevonedistat	45-52	NEDD8 activating enzyme E1 subunit 1	Homo sapiens	115-119
31057046-5	2019	Consistent with previous studies, treatment of asynchronous cells with MLN4924 increased CDT1 expression levels, induced G2 arrest and increased nuclear size.	pevonedistat	71-78	chromatin licensing and DNA replication factor 1	Homo sapiens	89-93
31057046-8	2019	Finally, treatment of mitotic cells with MLN4924 induced the premature accumulation of MKLP1 at the cleavage furrow, a key regulator of cytokinesis, which was concomitant with increased abscission delay and failure.	pevonedistat	41-48	kinesin family member 23	Homo sapiens	87-92
31057046-9	2019	Thus, these studies uncover an uncharacterized mitotic effect of MLN4924 on MKLP1 accumulation at the midbody and support a role for neddylation during cytokinesis.	pevonedistat	65-72	kinesin family member 23	Homo sapiens	76-81
30943988-2	2019	The process of protein neddylation is overactivated in multiple human cancers, providing a sound rationale for its targeting as an attractive anticancer therapeutic strategy, as evidence by the development of NEDD8-activating enzyme (NAE) inhibitor MLN4924 (also known as pevonedistat).	pevonedistat	272-284	NEDD8 ubiquitin like modifier	Homo sapiens	209-214
31178972-7	2019	Collectively, these findings demonstrate the neuroprotective role of MLN4924 against oxidative stress in SCIR injury via Sirt1.	pevonedistat	69-76	sirtuin 1	Rattus norvegicus	121-126
30781952-5	2019	The efficacy of this approach is validated through experiments with both synthetic mixtures of Escherichia coli ribosomes spiked into human cell lysates at known ratios and the quantitative evaluation of the human proteome"s response to the inhibition of cullin-based protein ubiquitination via the small molecule MLN4924.	pevonedistat	314-321	CDK2 associated cullin domain 1	Homo sapiens	255-261
30986950-7	2019	The first-in-class CRL inhibitory compound Pevonedistat (also called MLN4924) is currently under investigation as an anti-tumor drug in several clinical trials.	pevonedistat	43-55	interleukin 31 receptor A	Homo sapiens	19-22
30986950-7	2019	The first-in-class CRL inhibitory compound Pevonedistat (also called MLN4924) is currently under investigation as an anti-tumor drug in several clinical trials.	pevonedistat	69-76	interleukin 31 receptor A	Homo sapiens	19-22
28838998-4	2018	Treatment of HNSCC with the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924), which inhibits all cullin-based ligases, induces significant rereplication and inhibits HNSCC cell proliferation in culture and HNSCC xenografts in mice.	pevonedistat	62-74	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	28-33
30535233-4	2019	We inhibited them using MLN4924, an inhibitor of SCF complex ligases controlled by neddylation.	pevonedistat	24-31	KIT ligand	Bos taurus	49-52
30535233-10	2019	To detect the proteins affected by MLN4924 treatment, we performed a Western blot analysis of selected proteins (SMAD4, ribosomal protein S6, centromeric protein E, P27, NFKB inhibitor alpha, RNA-binding motif protein 19).	pevonedistat	35-42	SMAD family member 4	Bos taurus	113-118
30535233-10	2019	To detect the proteins affected by MLN4924 treatment, we performed a Western blot analysis of selected proteins (SMAD4, ribosomal protein S6, centromeric protein E, P27, NFKB inhibitor alpha, RNA-binding motif protein 19).	pevonedistat	35-42	40S ribosomal protein S6	Bos taurus	120-140
30535233-10	2019	To detect the proteins affected by MLN4924 treatment, we performed a Western blot analysis of selected proteins (SMAD4, ribosomal protein S6, centromeric protein E, P27, NFKB inhibitor alpha, RNA-binding motif protein 19).	pevonedistat	35-42	NFKB inhibitor alpha	Bos taurus	165-190
30535233-10	2019	To detect the proteins affected by MLN4924 treatment, we performed a Western blot analysis of selected proteins (SMAD4, ribosomal protein S6, centromeric protein E, P27, NFKB inhibitor alpha, RNA-binding motif protein 19).	pevonedistat	35-42	RNA binding motif protein 19	Bos taurus	192-220
30341788-0	2019	The Nedd8-activating enzyme inhibitor MLN4924 (TAK-924/Pevonedistat) induces apoptosis via c-Myc-Noxa axis in head and neck squamous cell carcinoma.	pevonedistat	38-45	NEDD8 ubiquitin like modifier	Homo sapiens	4-9
30341788-0	2019	The Nedd8-activating enzyme inhibitor MLN4924 (TAK-924/Pevonedistat) induces apoptosis via c-Myc-Noxa axis in head and neck squamous cell carcinoma.	pevonedistat	38-45	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	91-96
30341788-0	2019	The Nedd8-activating enzyme inhibitor MLN4924 (TAK-924/Pevonedistat) induces apoptosis via c-Myc-Noxa axis in head and neck squamous cell carcinoma.	pevonedistat	38-45	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	97-101
30341788-0	2019	The Nedd8-activating enzyme inhibitor MLN4924 (TAK-924/Pevonedistat) induces apoptosis via c-Myc-Noxa axis in head and neck squamous cell carcinoma.	pevonedistat	55-67	NEDD8 ubiquitin like modifier	Homo sapiens	4-9
30341788-0	2019	The Nedd8-activating enzyme inhibitor MLN4924 (TAK-924/Pevonedistat) induces apoptosis via c-Myc-Noxa axis in head and neck squamous cell carcinoma.	pevonedistat	55-67	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	91-96
30341788-0	2019	The Nedd8-activating enzyme inhibitor MLN4924 (TAK-924/Pevonedistat) induces apoptosis via c-Myc-Noxa axis in head and neck squamous cell carcinoma.	pevonedistat	55-67	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	97-101
29781056-0	2019	Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.	pevonedistat	18-30	NEDD8 ubiquitin like modifier	Homo sapiens	34-39
30563767-8	2019	In addition, treatment with MLN4924, an inhibitor of NEDD8-activating Enzyme, reduces the interaction between PCNA and RAD18, which blocks the localization of RAD18 to form foci, and thus inhibiting polymerase eta recruitment after oxidative stress.	pevonedistat	28-35	NEDD8 ubiquitin like modifier	Homo sapiens	53-58
30563767-8	2019	In addition, treatment with MLN4924, an inhibitor of NEDD8-activating Enzyme, reduces the interaction between PCNA and RAD18, which blocks the localization of RAD18 to form foci, and thus inhibiting polymerase eta recruitment after oxidative stress.	pevonedistat	28-35	proliferating cell nuclear antigen	Homo sapiens	110-114
30563767-8	2019	In addition, treatment with MLN4924, an inhibitor of NEDD8-activating Enzyme, reduces the interaction between PCNA and RAD18, which blocks the localization of RAD18 to form foci, and thus inhibiting polymerase eta recruitment after oxidative stress.	pevonedistat	28-35	RAD18 E3 ubiquitin protein ligase	Homo sapiens	119-124
30563767-8	2019	In addition, treatment with MLN4924, an inhibitor of NEDD8-activating Enzyme, reduces the interaction between PCNA and RAD18, which blocks the localization of RAD18 to form foci, and thus inhibiting polymerase eta recruitment after oxidative stress.	pevonedistat	28-35	RAD18 E3 ubiquitin protein ligase	Homo sapiens	159-164
30556867-0	2018	MRFAP1 plays a protective role in neddylation inhibitor MLN4924-mediated gastric cancer cell death.	pevonedistat	56-63	Morf4 family associated protein 1	Homo sapiens	0-6
30101447-3	2018	Pevonedistat (MLN4924) is a potent and selective small molecule NEDD8-activating enzyme inhibitor.	pevonedistat	0-12	NEDD8 ubiquitin like modifier	Canis lupus familiaris	64-69
30101447-3	2018	Pevonedistat (MLN4924) is a potent and selective small molecule NEDD8-activating enzyme inhibitor.	pevonedistat	14-21	NEDD8 ubiquitin like modifier	Canis lupus familiaris	64-69
30101447-4	2018	In human activated B-cell-like (ABC) diffuse large B-cell lymphoma, pevonedistat induces lymphoma cell apoptosis, DNA damage and G1 cell cycle arrest by inhibiting the nuclear factor-kappaB (NF-kappaB) pathway.	pevonedistat	68-80	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	9-30
30101447-4	2018	In human activated B-cell-like (ABC) diffuse large B-cell lymphoma, pevonedistat induces lymphoma cell apoptosis, DNA damage and G1 cell cycle arrest by inhibiting the nuclear factor-kappaB (NF-kappaB) pathway.	pevonedistat	68-80	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	32-35
30402022-0	2018	The Nedd8-activating enzyme inhibitor MLN4924 suppresses colon cancer cell growth via triggering autophagy.	pevonedistat	38-45	NEDD8 ubiquitin like modifier	Homo sapiens	4-9
30020196-2	2018	In this study, we evaluated the antitumor potential of MLN4924 (pevonedistat), a potent NEDD8 inhibitor.	pevonedistat	55-62	NEDD8 ubiquitin like modifier	Homo sapiens	88-93
30020196-2	2018	In this study, we evaluated the antitumor potential of MLN4924 (pevonedistat), a potent NEDD8 inhibitor.	pevonedistat	64-76	NEDD8 ubiquitin like modifier	Homo sapiens	88-93
29667067-0	2018	A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.	pevonedistat	28-35	ubiquitin conjugating enzyme E2 M	Homo sapiens	150-155
29667067-0	2018	A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.	pevonedistat	37-49	ubiquitin conjugating enzyme E2 M	Homo sapiens	150-155
29331584-4	2018	Indeed, neddylation inactivation by MLN4924 (also known as pevonedistat), a small molecule inhibitor of E1 NEDD8-activating enzyme currently in phase I/II clinical trials, exerts significant anticancer effects by inducing cell cycle arrest, apoptosis, senescence and autophagy in a cell-type and context dependent manner.	pevonedistat	59-71	NEDD8 ubiquitin like modifier	Homo sapiens	107-112
29321163-4	2018	In support of this hypothesis, we demonstrated that the NAE1 inhibitor MLN4924 induced G2-M-phase arrest and apoptosis in bulk CML cells with wild-type p53, regardless of their T315I mutation status in BCR-ABL.	pevonedistat	71-78	NEDD8 activating enzyme E1 subunit 1	Mus musculus	56-60
29321163-4	2018	In support of this hypothesis, we demonstrated that the NAE1 inhibitor MLN4924 induced G2-M-phase arrest and apoptosis in bulk CML cells with wild-type p53, regardless of their T315I mutation status in BCR-ABL.	pevonedistat	71-78	transformation related protein 53, pseudogene	Mus musculus	152-155
30699367-5	2019	We found that inhibition of neddylation with pevonedistat partially inhibited mTOR signaling transduction and vice versa, inhibition of mTOR signaling with sapanisertib partially inhibited neddylation in AML cell lines.	pevonedistat	45-57	mechanistic target of rapamycin kinase	Homo sapiens	78-82
30041665-14	2018	Hakai interacted with Ajuba via its HYB domain and induced Ajuba neddylation, which was antagonized by the neddylation inhibitor, MLN4924, but not MG132.	pevonedistat	130-137	Cbl proto-oncogene like 1	Homo sapiens	0-5
30041665-14	2018	Hakai interacted with Ajuba via its HYB domain and induced Ajuba neddylation, which was antagonized by the neddylation inhibitor, MLN4924, but not MG132.	pevonedistat	130-137	ajuba LIM protein	Homo sapiens	22-27
30041665-14	2018	Hakai interacted with Ajuba via its HYB domain and induced Ajuba neddylation, which was antagonized by the neddylation inhibitor, MLN4924, but not MG132.	pevonedistat	130-137	ajuba LIM protein	Homo sapiens	59-64
28838998-4	2018	Treatment of HNSCC with the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924), which inhibits all cullin-based ligases, induces significant rereplication and inhibits HNSCC cell proliferation in culture and HNSCC xenografts in mice.	pevonedistat	76-83	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	28-33
29464016-3	2018	However, in pevonedistat-treated ALL cell lines, we found consistent activation of the pro-survival MEK/ERK pathway, which has been associated with relapse and poor outcome in ALL.	pevonedistat	12-24	mitogen-activated protein kinase 1	Homo sapiens	104-107
29434977-1	2018	Inhibiting the protein neddylation pathway using the NEDD8-activating enzyme inhibitor MLN4924 represents an attractive anticancer strategy having been demonstrated to exhibit promising anticancer efficacy and with tolerable levels of toxicity; however, the mechanism by which MLN4924 inhibits cell proliferation in human esophageal squamous cell carcinoma (ESCC) cells requires further investigation.	pevonedistat	87-94	NEDD8 ubiquitin like modifier	Homo sapiens	53-58
29464016-2	2018	We previously identified that pevonedistat (TAK-924, MLN4924), a first-in-class inhibitor of NEDD8 activating enzyme (NAE), elicits ER stress and has potent in vitro and in vivo efficacy against ALL.	pevonedistat	30-42	NEDD8 ubiquitin like modifier	Homo sapiens	93-98
29464016-2	2018	We previously identified that pevonedistat (TAK-924, MLN4924), a first-in-class inhibitor of NEDD8 activating enzyme (NAE), elicits ER stress and has potent in vitro and in vivo efficacy against ALL.	pevonedistat	53-60	NEDD8 ubiquitin like modifier	Homo sapiens	93-98
29464016-4	2018	We uncovered that inhibition of the MEK/ERK pathway in vitro and in vivo sensitized ALL cells to pevonedistat.	pevonedistat	97-109	mitogen-activated protein kinase kinase 7	Homo sapiens	36-39
29464016-3	2018	However, in pevonedistat-treated ALL cell lines, we found consistent activation of the pro-survival MEK/ERK pathway, which has been associated with relapse and poor outcome in ALL.	pevonedistat	12-24	mitogen-activated protein kinase kinase 7	Homo sapiens	100-103
29464016-4	2018	We uncovered that inhibition of the MEK/ERK pathway in vitro and in vivo sensitized ALL cells to pevonedistat.	pevonedistat	97-109	mitogen-activated protein kinase 1	Homo sapiens	40-43
29464016-6	2018	Mechanistically, Ca2+ influx via the Ca2+-release-activated Ca2+ (CRAC) channel induced protein kinase C beta2 (PKC-beta2) was responsible for activation of the MEK/ERK pathway in pevonedistat-treated ALL cells.	pevonedistat	180-192	mitogen-activated protein kinase kinase 7	Homo sapiens	161-164
29464016-6	2018	Mechanistically, Ca2+ influx via the Ca2+-release-activated Ca2+ (CRAC) channel induced protein kinase C beta2 (PKC-beta2) was responsible for activation of the MEK/ERK pathway in pevonedistat-treated ALL cells.	pevonedistat	180-192	mitogen-activated protein kinase 1	Homo sapiens	165-168
29464016-9	2018	Further, we identified eIF2alpha as an important post-transcriptional regulator of STIM1, suggesting that pevonedistat-induced eIF2alpha de-phosphorylation selectively down-regulates translation of STIM1 mRNA.	pevonedistat	106-118	eukaryotic translation initiation factor 2A	Homo sapiens	23-32
29464016-9	2018	Further, we identified eIF2alpha as an important post-transcriptional regulator of STIM1, suggesting that pevonedistat-induced eIF2alpha de-phosphorylation selectively down-regulates translation of STIM1 mRNA.	pevonedistat	106-118	stromal interaction molecule 1	Homo sapiens	83-88
29464016-9	2018	Further, we identified eIF2alpha as an important post-transcriptional regulator of STIM1, suggesting that pevonedistat-induced eIF2alpha de-phosphorylation selectively down-regulates translation of STIM1 mRNA.	pevonedistat	106-118	eukaryotic translation initiation factor 2A	Homo sapiens	127-136
29464016-9	2018	Further, we identified eIF2alpha as an important post-transcriptional regulator of STIM1, suggesting that pevonedistat-induced eIF2alpha de-phosphorylation selectively down-regulates translation of STIM1 mRNA.	pevonedistat	106-118	stromal interaction molecule 1	Homo sapiens	198-203
29464016-10	2018	Consequently, our data suggest that pevonedistat potentially activates SOCE and promotes Ca2+ influx leading to activation of the MEK/ERK pathway by altering the stoichiometric Orai1:STIM1 ratio and inducing ER stress in ALL cells.	pevonedistat	36-48	mitogen-activated protein kinase kinase 7	Homo sapiens	130-133
29464016-10	2018	Consequently, our data suggest that pevonedistat potentially activates SOCE and promotes Ca2+ influx leading to activation of the MEK/ERK pathway by altering the stoichiometric Orai1:STIM1 ratio and inducing ER stress in ALL cells.	pevonedistat	36-48	mitogen-activated protein kinase 1	Homo sapiens	134-137
29464016-10	2018	Consequently, our data suggest that pevonedistat potentially activates SOCE and promotes Ca2+ influx leading to activation of the MEK/ERK pathway by altering the stoichiometric Orai1:STIM1 ratio and inducing ER stress in ALL cells.	pevonedistat	36-48	ORAI calcium release-activated calcium modulator 1	Homo sapiens	177-182
29464016-10	2018	Consequently, our data suggest that pevonedistat potentially activates SOCE and promotes Ca2+ influx leading to activation of the MEK/ERK pathway by altering the stoichiometric Orai1:STIM1 ratio and inducing ER stress in ALL cells.	pevonedistat	36-48	stromal interaction molecule 1	Homo sapiens	183-188
28177892-0	2017	Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis.	pevonedistat	0-12	NEDD8 ubiquitin like modifier	Homo sapiens	16-21
28663057-0	2017	Inhibition of Mcl-1 enhances Pevonedistat-triggered apoptosis in osteosarcoma cells.	pevonedistat	29-41	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	14-19
28663057-4	2017	Because Mcl-1 is an important anti-apoptotic protein and also because apoptosis has been shown to be a major cell death pathway, we hypothesized that Mcl-1 accumulation negatively impacted Pevonedistat-mediated anticancer activity in OS cells.	pevonedistat	189-201	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	8-13
28701396-0	2017	Effects of the NEDD8-Activating Enzyme Inhibitor MLN4924 on Lytic Reactivation of Kaposi"s Sarcoma-Associated Herpesvirus.	pevonedistat	49-56	NEDD8 ubiquitin like modifier	Homo sapiens	15-20
28663057-4	2017	Because Mcl-1 is an important anti-apoptotic protein and also because apoptosis has been shown to be a major cell death pathway, we hypothesized that Mcl-1 accumulation negatively impacted Pevonedistat-mediated anticancer activity in OS cells.	pevonedistat	189-201	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	150-155
28663057-6	2017	We found that inhibition of Mcl-1 expression by siRNA considerably enhanced Pevonedistat-triggered the activation of caspase-3, PARP cleavage and apoptosis, and also dramatically promoted the ability of Pevonedistat to inhibit colony formation of OS cells.	pevonedistat	76-88	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	28-33
28663057-6	2017	We found that inhibition of Mcl-1 expression by siRNA considerably enhanced Pevonedistat-triggered the activation of caspase-3, PARP cleavage and apoptosis, and also dramatically promoted the ability of Pevonedistat to inhibit colony formation of OS cells.	pevonedistat	76-88	caspase 3	Homo sapiens	117-126
28663057-6	2017	We found that inhibition of Mcl-1 expression by siRNA considerably enhanced Pevonedistat-triggered the activation of caspase-3, PARP cleavage and apoptosis, and also dramatically promoted the ability of Pevonedistat to inhibit colony formation of OS cells.	pevonedistat	76-88	poly(ADP-ribose) polymerase 1	Homo sapiens	128-132
28663057-6	2017	We found that inhibition of Mcl-1 expression by siRNA considerably enhanced Pevonedistat-triggered the activation of caspase-3, PARP cleavage and apoptosis, and also dramatically promoted the ability of Pevonedistat to inhibit colony formation of OS cells.	pevonedistat	203-215	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	28-33
28663057-6	2017	We found that inhibition of Mcl-1 expression by siRNA considerably enhanced Pevonedistat-triggered the activation of caspase-3, PARP cleavage and apoptosis, and also dramatically promoted the ability of Pevonedistat to inhibit colony formation of OS cells.	pevonedistat	203-215	poly(ADP-ribose) polymerase 1	Homo sapiens	128-132
28663057-8	2017	Altogether, our study shows that Mcl-1 is a critical resistance factor to Pevonedistat monotherapy, and suggests that Pevonedistat in combinations with flavopiridol may achieve better anticancer therapy.	pevonedistat	74-86	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	33-38
28663057-8	2017	Altogether, our study shows that Mcl-1 is a critical resistance factor to Pevonedistat monotherapy, and suggests that Pevonedistat in combinations with flavopiridol may achieve better anticancer therapy.	pevonedistat	118-130	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	33-38
28892104-3	2017	The NEDD8-activating enzyme inhibitor pevonedistat (MLN4924, TAK-924) is an investigational drug with antiproliferative activities in AML, and is also reported to induce cell differentiation.	pevonedistat	38-50	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	4-9
28892104-3	2017	The NEDD8-activating enzyme inhibitor pevonedistat (MLN4924, TAK-924) is an investigational drug with antiproliferative activities in AML, and is also reported to induce cell differentiation.	pevonedistat	52-59	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	4-9
28669728-5	2017	Further mechanistic study revealed that MLN4924-induced apoptosis was mediated by substantial up-regulation of pro-apoptotic NOXA.	pevonedistat	40-47	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	125-129
28450112-0	2017	NEDD8-activating enzyme inhibitor, MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis through up-regulation of ATF-4.	pevonedistat	35-42	NEDD8 ubiquitin like modifier	Homo sapiens	0-5
28450112-0	2017	NEDD8-activating enzyme inhibitor, MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis through up-regulation of ATF-4.	pevonedistat	35-42	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	66-70
28450112-0	2017	NEDD8-activating enzyme inhibitor, MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis through up-regulation of ATF-4.	pevonedistat	35-42	activating transcription factor 4	Homo sapiens	116-121
28450112-0	2017	NEDD8-activating enzyme inhibitor, MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis through up-regulation of ATF-4.	pevonedistat	44-56	NEDD8 ubiquitin like modifier	Homo sapiens	0-5
28450112-0	2017	NEDD8-activating enzyme inhibitor, MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis through up-regulation of ATF-4.	pevonedistat	44-56	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	66-70
28450112-0	2017	NEDD8-activating enzyme inhibitor, MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis through up-regulation of ATF-4.	pevonedistat	44-56	activating transcription factor 4	Homo sapiens	116-121
28177892-3	2017	We and others have shown that pevonedistat, an investigational inhibitor of the NEDD8-activating enzyme, abrogates NFkappaB activity in B-cell neoplasia.	pevonedistat	30-42	NEDD8 ubiquitin like modifier	Homo sapiens	80-85
28177892-3	2017	We and others have shown that pevonedistat, an investigational inhibitor of the NEDD8-activating enzyme, abrogates NFkappaB activity in B-cell neoplasia.	pevonedistat	30-42	nuclear factor kappa B subunit 1	Homo sapiens	115-123
28177892-5	2017	Pevonedistat enhanced caspase-8 processing following death receptor ligation, and downmodulated cFLIP, a NFkappaB-regulated protease-deficient caspase homolog.	pevonedistat	0-12	caspase 8	Homo sapiens	22-31
28177892-5	2017	Pevonedistat enhanced caspase-8 processing following death receptor ligation, and downmodulated cFLIP, a NFkappaB-regulated protease-deficient caspase homolog.	pevonedistat	0-12	nuclear factor kappa B subunit 1	Homo sapiens	105-113
28216678-3	2017	Human umbilical vein endothelial cells treated with MLN4924, an inhibitor of NEDD8-activating enzyme, or with CUL3 siRNA drastically lost their response to VEGF due to the intense decrease in VEGFR2 expression.	pevonedistat	52-59	NEDD8 ubiquitin like modifier	Homo sapiens	77-82
28216678-3	2017	Human umbilical vein endothelial cells treated with MLN4924, an inhibitor of NEDD8-activating enzyme, or with CUL3 siRNA drastically lost their response to VEGF due to the intense decrease in VEGFR2 expression.	pevonedistat	52-59	vascular endothelial growth factor A	Homo sapiens	156-160
28216678-3	2017	Human umbilical vein endothelial cells treated with MLN4924, an inhibitor of NEDD8-activating enzyme, or with CUL3 siRNA drastically lost their response to VEGF due to the intense decrease in VEGFR2 expression.	pevonedistat	52-59	kinase insert domain receptor	Homo sapiens	192-198
27901050-0	2016	The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity.	pevonedistat	31-38	NEDD8 ubiquitin like modifier	Danio rerio	15-20
27783255-0	2017	Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).	pevonedistat	100-112	NEDD8 ubiquitin like modifier	Homo sapiens	66-71
27783255-2	2017	Pevonedistat (MLN4924) is a selective small molecule targeting the NEDD8-activating enzyme (NAE) and inhibits an early step in neddylation, resulting in DNA re-replication, cell cycle arrest and death.	pevonedistat	0-12	NEDD8 ubiquitin like modifier	Homo sapiens	67-72
27815049-0	2017	Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice.	pevonedistat	60-72	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	25-30
27815049-4	2017	Here we report that pevonedistat (MLN4924), an inhibitor of the Nedd8-activating enzyme, which functions upstream of the proteasome in the ubiquitin-proteasome pathway, can also show similar protective effects.	pevonedistat	20-32	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	64-69
27815049-4	2017	Here we report that pevonedistat (MLN4924), an inhibitor of the Nedd8-activating enzyme, which functions upstream of the proteasome in the ubiquitin-proteasome pathway, can also show similar protective effects.	pevonedistat	34-41	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	64-69
27771247-0	2016	An inhibitor of apoptosis protein antagonist T-3256336 potentiates the antitumor efficacy of the Nedd8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924).	pevonedistat	131-143	NEDD8 ubiquitin like modifier	Homo sapiens	97-102
27771247-3	2016	In this study, we showed that T-3256336, the orally available IAP antagonist has synergistically enhances the antiproliferative effects of the NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924), and these effects were attenuated by a TNFalpha-neutralizing antibody.	pevonedistat	183-195	alkaline phosphatase, intestinal	Homo sapiens	62-65
27771247-3	2016	In this study, we showed that T-3256336, the orally available IAP antagonist has synergistically enhances the antiproliferative effects of the NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924), and these effects were attenuated by a TNFalpha-neutralizing antibody.	pevonedistat	183-195	NEDD8 ubiquitin like modifier	Homo sapiens	143-148
27771247-4	2016	In the present mechanistic analyses, pevonedistat induced TNFalpha mRNA and triggered IAP antagonist-dependent extrinsic apoptotic cell death in cancer cell lines.	pevonedistat	37-49	tumor necrosis factor	Homo sapiens	58-66
27771247-4	2016	In the present mechanistic analyses, pevonedistat induced TNFalpha mRNA and triggered IAP antagonist-dependent extrinsic apoptotic cell death in cancer cell lines.	pevonedistat	37-49	alkaline phosphatase, intestinal	Homo sapiens	86-89
27901050-0	2016	The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity.	pevonedistat	31-38	tumor protein p53	Danio rerio	102-105
27901050-0	2016	The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity.	pevonedistat	40-52	NEDD8 ubiquitin like modifier	Danio rerio	15-20
27901050-0	2016	The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity.	pevonedistat	40-52	tumor protein p53	Danio rerio	102-105
27771609-1	2017	Background: The NEDD8 conjugation pathway modulates the ubiquitination and activity of a wide range of intracellular proteins, and its blockade by pevonedistat is emerging as a promising therapeutic approach in various cancer settings.	pevonedistat	147-159	NEDD8 ubiquitin like modifier	Homo sapiens	16-21
27626202-0	2016	The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2alpha and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia.	pevonedistat	38-50	NEDD8 ubiquitin like modifier	Homo sapiens	4-9
27626202-0	2016	The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2alpha and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia.	pevonedistat	38-50	eukaryotic translation initiation factor 2A	Homo sapiens	65-74
27626202-0	2016	The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2alpha and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia.	pevonedistat	38-50	mechanistic target of rapamycin kinase	Homo sapiens	79-83
27626202-4	2016	We investigated the antineoplastic activity of pevonedistat , a novel NEDD8-activating enzyme inhibitor that targets E3 cullin-RING ligases (CRLs) dependent proteasomal protein degradation, in ALL.	pevonedistat	47-59	NEDD8 ubiquitin like modifier	Homo sapiens	70-75
27626202-6	2016	Mechanistically, pevonedistat led to P-eIF2a dephosphorylation causing atypical proteotoxic/ER stress from failure to halt protein translation via the UPR and upregulation of mTOR/p70S6K.	pevonedistat	17-29	eukaryotic translation initiation factor 2A	Homo sapiens	39-44
27626202-6	2016	Mechanistically, pevonedistat led to P-eIF2a dephosphorylation causing atypical proteotoxic/ER stress from failure to halt protein translation via the UPR and upregulation of mTOR/p70S6K.	pevonedistat	17-29	mechanistic target of rapamycin kinase	Homo sapiens	175-179
27626202-6	2016	Mechanistically, pevonedistat led to P-eIF2a dephosphorylation causing atypical proteotoxic/ER stress from failure to halt protein translation via the UPR and upregulation of mTOR/p70S6K.	pevonedistat	17-29	ribosomal protein S6 kinase B1	Homo sapiens	180-186
27626202-7	2016	Additional studies revealed that pevonedistat re-balanced the homeostasis of pro- and anti-apoptotic proteins to favor cell death through altered expression and/or activity of Mcl-1, NOXA, and BIM, suggesting that pevonedistat has a "priming" effect on ALL by altering the apoptotic threshold through modulation of Mcl-1 activity.	pevonedistat	33-45	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	176-181
27626202-7	2016	Additional studies revealed that pevonedistat re-balanced the homeostasis of pro- and anti-apoptotic proteins to favor cell death through altered expression and/or activity of Mcl-1, NOXA, and BIM, suggesting that pevonedistat has a "priming" effect on ALL by altering the apoptotic threshold through modulation of Mcl-1 activity.	pevonedistat	33-45	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	183-187
27626202-7	2016	Additional studies revealed that pevonedistat re-balanced the homeostasis of pro- and anti-apoptotic proteins to favor cell death through altered expression and/or activity of Mcl-1, NOXA, and BIM, suggesting that pevonedistat has a "priming" effect on ALL by altering the apoptotic threshold through modulation of Mcl-1 activity.	pevonedistat	33-45	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	315-320
27626202-7	2016	Additional studies revealed that pevonedistat re-balanced the homeostasis of pro- and anti-apoptotic proteins to favor cell death through altered expression and/or activity of Mcl-1, NOXA, and BIM, suggesting that pevonedistat has a "priming" effect on ALL by altering the apoptotic threshold through modulation of Mcl-1 activity.	pevonedistat	214-226	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	176-181
27626202-7	2016	Additional studies revealed that pevonedistat re-balanced the homeostasis of pro- and anti-apoptotic proteins to favor cell death through altered expression and/or activity of Mcl-1, NOXA, and BIM, suggesting that pevonedistat has a "priming" effect on ALL by altering the apoptotic threshold through modulation of Mcl-1 activity.	pevonedistat	214-226	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	315-320
27771609-9	2017	Pevonedistat sensitivity did not statistically significantly correlate with microsatellite instability or mutations in KRAS or BRAF and was functionally associated with low EGFR pathway activity.	pevonedistat	0-12	epidermal growth factor receptor	Homo sapiens	173-177
27388524-0	2016	Corrigendum to "The MLN4924 inhibitor exerts a neuroprotective effect against oxidative stress injury via Nrf2 protein accumulation" [Redox Biol.	pevonedistat	20-27	NFE2 like bZIP transcription factor 2	Homo sapiens	106-110
27333051-10	2016	These findings demonstrate that the CRL4-CDT2-SET8/p21 degradation axis is the primary target of inhibition by pevonedistat in melanoma and suggest that a broad patient population may benefit from pevonedistat therapy.	pevonedistat	197-209	H3 histone pseudogene 16	Homo sapiens	51-54
27528738-0	2016	Correction: The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF-kappaB Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells.	pevonedistat	50-57	NEDD8 ubiquitin like modifier	Homo sapiens	16-21
27333051-0	2016	Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.	pevonedistat	113-125	interleukin 17 receptor B	Homo sapiens	20-24
27682585-3	2016	Initial in vitro studies using cultured intestinal epithelial cells revealed that the neddylation inhibitor MLN4924 prominently induces the deneddylation of Cullin-1.	pevonedistat	108-115	cullin 1	Homo sapiens	157-165
27333051-13	2016	CDT2 is required for melanoma cell proliferation and inhibition of CRL4(CDT2) by pevonedistat suppresses melanoma in vitro and in vivo through the induction of DNA rereplication and senescence through the stabilization of the CRL4(CDT2) substrates p21 and SET8.	pevonedistat	81-93	denticleless E3 ubiquitin protein ligase homolog	Homo sapiens	0-4
27333051-0	2016	Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.	pevonedistat	113-125	denticleless E3 ubiquitin protein ligase homolog	Homo sapiens	25-29
27333051-13	2016	CDT2 is required for melanoma cell proliferation and inhibition of CRL4(CDT2) by pevonedistat suppresses melanoma in vitro and in vivo through the induction of DNA rereplication and senescence through the stabilization of the CRL4(CDT2) substrates p21 and SET8.	pevonedistat	81-93	interleukin 17 receptor B	Homo sapiens	67-71
27333051-0	2016	Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.	pevonedistat	113-125	lysine methyltransferase 5A	Homo sapiens	30-34
27333051-0	2016	Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.	pevonedistat	113-125	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	35-38
27333051-5	2016	Pevonedistat (MLN4924), a specific inhibitor of the NEDD8 activating enzyme (NAE), inhibits the activity of cullin E3 ligases, thereby stabilizing a vast number of cullin substrates and resulting in cancer cell inhibition in vitro and tumor suppression in nude mice.	pevonedistat	0-12	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	52-57
27333051-5	2016	Pevonedistat (MLN4924), a specific inhibitor of the NEDD8 activating enzyme (NAE), inhibits the activity of cullin E3 ligases, thereby stabilizing a vast number of cullin substrates and resulting in cancer cell inhibition in vitro and tumor suppression in nude mice.	pevonedistat	14-21	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	52-57
27333051-7	2016	CRISPR/Cas9-mediated heterozygous deletion of CDKN1A (encoding p21) or SET8 in melanoma cells demonstrated that the rereplication-mediated cytotoxicity of pevonedistat is mediated through preventing the degradation of p21 and SET8 and is essential for melanoma suppression in nude mice.	pevonedistat	155-167	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	46-52
27333051-7	2016	CRISPR/Cas9-mediated heterozygous deletion of CDKN1A (encoding p21) or SET8 in melanoma cells demonstrated that the rereplication-mediated cytotoxicity of pevonedistat is mediated through preventing the degradation of p21 and SET8 and is essential for melanoma suppression in nude mice.	pevonedistat	155-167	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	63-66
27333051-7	2016	CRISPR/Cas9-mediated heterozygous deletion of CDKN1A (encoding p21) or SET8 in melanoma cells demonstrated that the rereplication-mediated cytotoxicity of pevonedistat is mediated through preventing the degradation of p21 and SET8 and is essential for melanoma suppression in nude mice.	pevonedistat	155-167	lysine methyltransferase 5A	Homo sapiens	71-75
27333051-7	2016	CRISPR/Cas9-mediated heterozygous deletion of CDKN1A (encoding p21) or SET8 in melanoma cells demonstrated that the rereplication-mediated cytotoxicity of pevonedistat is mediated through preventing the degradation of p21 and SET8 and is essential for melanoma suppression in nude mice.	pevonedistat	155-167	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	218-221
27333051-7	2016	CRISPR/Cas9-mediated heterozygous deletion of CDKN1A (encoding p21) or SET8 in melanoma cells demonstrated that the rereplication-mediated cytotoxicity of pevonedistat is mediated through preventing the degradation of p21 and SET8 and is essential for melanoma suppression in nude mice.	pevonedistat	155-167	lysine methyltransferase 5A	Homo sapiens	226-230
27333051-8	2016	By contrast, pevonedistat-induced transient growth suppression was independent of p21 or SET8, and insufficient to inhibit tumor growth in vivo.	pevonedistat	13-25	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	82-85
27333051-8	2016	By contrast, pevonedistat-induced transient growth suppression was independent of p21 or SET8, and insufficient to inhibit tumor growth in vivo.	pevonedistat	13-25	lysine methyltransferase 5A	Homo sapiens	89-93
27333051-9	2016	Pevonedistat additionally synergized with the BRAF kinase inhibitor PLX4720 to inhibit BRAF melanoma, and suppressed PLX4720-resistant melanoma cells.	pevonedistat	0-12	Braf transforming gene	Mus musculus	46-50
27333051-10	2016	These findings demonstrate that the CRL4-CDT2-SET8/p21 degradation axis is the primary target of inhibition by pevonedistat in melanoma and suggest that a broad patient population may benefit from pevonedistat therapy.	pevonedistat	111-123	interleukin 17 receptor B	Homo sapiens	36-40
27333051-10	2016	These findings demonstrate that the CRL4-CDT2-SET8/p21 degradation axis is the primary target of inhibition by pevonedistat in melanoma and suggest that a broad patient population may benefit from pevonedistat therapy.	pevonedistat	111-123	denticleless E3 ubiquitin protein ligase homolog	Homo sapiens	41-45
27333051-10	2016	These findings demonstrate that the CRL4-CDT2-SET8/p21 degradation axis is the primary target of inhibition by pevonedistat in melanoma and suggest that a broad patient population may benefit from pevonedistat therapy.	pevonedistat	111-123	lysine methyltransferase 5A	Homo sapiens	46-50
27333051-10	2016	These findings demonstrate that the CRL4-CDT2-SET8/p21 degradation axis is the primary target of inhibition by pevonedistat in melanoma and suggest that a broad patient population may benefit from pevonedistat therapy.	pevonedistat	111-123	H3 histone pseudogene 16	Homo sapiens	51-54
27333051-10	2016	These findings demonstrate that the CRL4-CDT2-SET8/p21 degradation axis is the primary target of inhibition by pevonedistat in melanoma and suggest that a broad patient population may benefit from pevonedistat therapy.	pevonedistat	197-209	interleukin 17 receptor B	Homo sapiens	36-40
27333051-10	2016	These findings demonstrate that the CRL4-CDT2-SET8/p21 degradation axis is the primary target of inhibition by pevonedistat in melanoma and suggest that a broad patient population may benefit from pevonedistat therapy.	pevonedistat	197-209	denticleless E3 ubiquitin protein ligase homolog	Homo sapiens	41-45
27333051-10	2016	These findings demonstrate that the CRL4-CDT2-SET8/p21 degradation axis is the primary target of inhibition by pevonedistat in melanoma and suggest that a broad patient population may benefit from pevonedistat therapy.	pevonedistat	197-209	lysine methyltransferase 5A	Homo sapiens	46-50
27056178-0	2016	A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.	pevonedistat	73-85	NEDD8 ubiquitin like modifier	Homo sapiens	39-44
27333051-13	2016	CDT2 is required for melanoma cell proliferation and inhibition of CRL4(CDT2) by pevonedistat suppresses melanoma in vitro and in vivo through the induction of DNA rereplication and senescence through the stabilization of the CRL4(CDT2) substrates p21 and SET8.	pevonedistat	81-93	denticleless E3 ubiquitin protein ligase homolog	Homo sapiens	72-76
27333051-13	2016	CDT2 is required for melanoma cell proliferation and inhibition of CRL4(CDT2) by pevonedistat suppresses melanoma in vitro and in vivo through the induction of DNA rereplication and senescence through the stabilization of the CRL4(CDT2) substrates p21 and SET8.	pevonedistat	81-93	interleukin 17 receptor B	Homo sapiens	226-230
27333051-13	2016	CDT2 is required for melanoma cell proliferation and inhibition of CRL4(CDT2) by pevonedistat suppresses melanoma in vitro and in vivo through the induction of DNA rereplication and senescence through the stabilization of the CRL4(CDT2) substrates p21 and SET8.	pevonedistat	81-93	denticleless E3 ubiquitin protein ligase homolog	Homo sapiens	72-76
27333051-13	2016	CDT2 is required for melanoma cell proliferation and inhibition of CRL4(CDT2) by pevonedistat suppresses melanoma in vitro and in vivo through the induction of DNA rereplication and senescence through the stabilization of the CRL4(CDT2) substrates p21 and SET8.	pevonedistat	81-93	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	248-251
27333051-13	2016	CDT2 is required for melanoma cell proliferation and inhibition of CRL4(CDT2) by pevonedistat suppresses melanoma in vitro and in vivo through the induction of DNA rereplication and senescence through the stabilization of the CRL4(CDT2) substrates p21 and SET8.	pevonedistat	81-93	lysine methyltransferase 5A	Homo sapiens	256-260
26966893-0	2016	The MLN4924 inhibitor exerts a neuroprotective effect against oxidative stress injury via Nrf2 protein accumulation.	pevonedistat	4-11	NFE2 like bZIP transcription factor 2	Homo sapiens	90-94
27224919-0	2016	Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells.	pevonedistat	76-83	NEDD8 ubiquitin like modifier	Homo sapiens	42-47
27378813-9	2016	The effects of CUL3 on ROMK expression in both oocytes and M-1 CCD cells was reduced by addition of the neddylation inhibitor, MLN4924.	pevonedistat	127-134	cullin 3	Mus musculus	15-19
27378813-9	2016	The effects of CUL3 on ROMK expression in both oocytes and M-1 CCD cells was reduced by addition of the neddylation inhibitor, MLN4924.	pevonedistat	127-134	potassium inwardly-rectifying channel, subfamily J, member 1	Mus musculus	23-27
27224919-0	2016	Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells.	pevonedistat	85-97	NEDD8 ubiquitin like modifier	Homo sapiens	42-47
27224919-2	2016	MLN4924 (also known as Pevonedistat), a specific inhibitor of NEDD8-activating enzyme, has recently entered phase I/II clinical trials in several malignancies.	pevonedistat	0-7	NEDD8 ubiquitin like modifier	Homo sapiens	62-67
27224919-2	2016	MLN4924 (also known as Pevonedistat), a specific inhibitor of NEDD8-activating enzyme, has recently entered phase I/II clinical trials in several malignancies.	pevonedistat	23-35	NEDD8 ubiquitin like modifier	Homo sapiens	62-67
26851293-0	2016	The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.	pevonedistat	18-30	histone deacetylase 9	Homo sapiens	50-54
27162365-1	2016	MLN4924, also known as pevonedistat, is the first-in-class inhibitor of NEDD8-activating enzyme, which blocks the entire neddylation modification of proteins.	pevonedistat	23-35	NEDD8 ubiquitin like modifier	Homo sapiens	72-77
26851293-2	2016	Here we examined mechanisms underlying interactions between the NAE inhibitor pevonedistat (MLN4924) and the approved HDAC inhibitor belinostat in AML/MDS cells.	pevonedistat	78-90	histone deacetylase 9	Homo sapiens	118-122
26993774-0	2016	The NEDD8-activating enzyme inhibitor MLN4924 induces G2 arrest and apoptosis in T-cell acute lymphoblastic leukemia.	pevonedistat	38-45	NEDD8 ubiquitin like modifier	Homo sapiens	4-9
26993774-1	2016	The first-in-class compound MLN4924 is a small molecule inhibitor that selectively inactivates NEDD8-activating enzyme (NAE).	pevonedistat	28-35	NEDD8 ubiquitin like modifier	Homo sapiens	95-100
26675347-0	2016	Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.	pevonedistat	0-12	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	16-21
26976604-7	2016	Besides dysregulating CRL-mediated cell proliferation and UV-induced apoptosis, IP5K depletion potentiates by 28-fold the cytotoxic effect of the neddylation inhibitor MLN4924.	pevonedistat	168-175	inositol-pentakisphosphate 2-kinase	Homo sapiens	80-84
26675347-4	2016	Of interest, in the MCL cell lines with lower half-maximal inhibitory concentration (0.1-0.5 muM), pevonedistat induced G1-phase cell cycle arrest, downregulation of Bcl-xL levels, decreased nuclear factor (NF)-kappaB activity, and apoptosis.	pevonedistat	99-111	BCL2-like 1	Mus musculus	166-172
26675347-8	2016	Our data suggest that pevonedistat has significant activity in MCL preclinical models, possibly related to effects on NF-kappaB activity, Bcl-xL downregulation, and G1 cell cycle arrest.	pevonedistat	22-34	BCL2-like 1	Mus musculus	138-144
26561559-0	2016	Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.	pevonedistat	77-89	NEDD8 ubiquitin like modifier	Homo sapiens	43-48
26423795-0	2016	Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.	pevonedistat	71-83	NEDD8 ubiquitin like modifier	Homo sapiens	37-42
26423795-1	2016	PURPOSE: To determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of the investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) and to investigate pevonedistat pharmacokinetics and pharmacodynamics in patients with advanced nonhematologic malignancies.	pevonedistat	154-166	NEDD8 ubiquitin like modifier	Homo sapiens	114-119
26423795-11	2016	NAE inhibition by pevonedistat was demonstrated in multiple tumor types via IHC detection of pevonedistat-NEDD8 adduct and accumulation of Cullin-RING ligase substrates CDT1 and NRF2 in tumor biopsies.	pevonedistat	18-30	NEDD8 ubiquitin like modifier	Homo sapiens	106-111
26423795-11	2016	NAE inhibition by pevonedistat was demonstrated in multiple tumor types via IHC detection of pevonedistat-NEDD8 adduct and accumulation of Cullin-RING ligase substrates CDT1 and NRF2 in tumor biopsies.	pevonedistat	18-30	chromatin licensing and DNA replication factor 1	Homo sapiens	169-173
26423795-11	2016	NAE inhibition by pevonedistat was demonstrated in multiple tumor types via IHC detection of pevonedistat-NEDD8 adduct and accumulation of Cullin-RING ligase substrates CDT1 and NRF2 in tumor biopsies.	pevonedistat	18-30	NFE2 like bZIP transcription factor 2	Homo sapiens	178-182
26423795-11	2016	NAE inhibition by pevonedistat was demonstrated in multiple tumor types via IHC detection of pevonedistat-NEDD8 adduct and accumulation of Cullin-RING ligase substrates CDT1 and NRF2 in tumor biopsies.	pevonedistat	93-105	NEDD8 ubiquitin like modifier	Homo sapiens	106-111
25867069-0	2016	The NEDD8 inhibitor MLN4924 increases the size of the nucleolus and activates p53 through the ribosomal-Mdm2 pathway.	pevonedistat	20-27	NEDD8 ubiquitin like modifier	Homo sapiens	4-9
25867069-0	2016	The NEDD8 inhibitor MLN4924 increases the size of the nucleolus and activates p53 through the ribosomal-Mdm2 pathway.	pevonedistat	20-27	tumor protein p53	Homo sapiens	78-81
25867069-0	2016	The NEDD8 inhibitor MLN4924 increases the size of the nucleolus and activates p53 through the ribosomal-Mdm2 pathway.	pevonedistat	20-27	MDM2 proto-oncogene	Homo sapiens	104-108
26561559-0	2016	Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.	pevonedistat	91-98	NEDD8 ubiquitin like modifier	Homo sapiens	43-48
26561559-1	2016	PURPOSE: Evaluate the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of the first-in-class investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in patients with relapsed/refractory lymphoma or multiple myeloma.	pevonedistat	181-193	NEDD8 ubiquitin like modifier	Homo sapiens	141-146
26561559-12	2016	Pevonedistat-NEDD8 adduct was detected in bone marrow aspirates, indicating pevonedistat target engagement in the bone marrow compartment.	pevonedistat	0-12	NEDD8 ubiquitin like modifier	Homo sapiens	13-18
26561559-12	2016	Pevonedistat-NEDD8 adduct was detected in bone marrow aspirates, indicating pevonedistat target engagement in the bone marrow compartment.	pevonedistat	76-88	NEDD8 ubiquitin like modifier	Homo sapiens	13-18
26156395-3	2015	The NEDD8 inhibitor MLN4924 selectively targets SCF(Skp2) activation and offers a more specific approach to protein degradation inhibition than total proteasomal inhibition.	pevonedistat	20-27	NEDD8 ubiquitin like modifier	Homo sapiens	4-9
26156395-3	2015	The NEDD8 inhibitor MLN4924 selectively targets SCF(Skp2) activation and offers a more specific approach to protein degradation inhibition than total proteasomal inhibition.	pevonedistat	20-27	KIT ligand	Homo sapiens	48-51
26156395-3	2015	The NEDD8 inhibitor MLN4924 selectively targets SCF(Skp2) activation and offers a more specific approach to protein degradation inhibition than total proteasomal inhibition.	pevonedistat	20-27	S-phase kinase associated protein 2	Homo sapiens	52-56
25615422-1	2015	MLN4924, a small molecule inhibitor of NEDD8 activating enzyme (NAE), has been reported to elicit an anti-tumor effect on various malignancies.	pevonedistat	0-7	NEDD8 ubiquitin like modifier	Homo sapiens	39-44
26676780-14	2015	The Nedd8 activation enzyme inhibitor MLN4924 blocks the activity of the host ubiquitin ligase that Vpu coopts to direct the degradation of CD4 and BST2.	pevonedistat	38-45	NEDD8 ubiquitin like modifier	Homo sapiens	4-9
26676780-14	2015	The Nedd8 activation enzyme inhibitor MLN4924 blocks the activity of the host ubiquitin ligase that Vpu coopts to direct the degradation of CD4 and BST2.	pevonedistat	38-45	Vpu	Human immunodeficiency virus 1	100-103
26676780-14	2015	The Nedd8 activation enzyme inhibitor MLN4924 blocks the activity of the host ubiquitin ligase that Vpu coopts to direct the degradation of CD4 and BST2.	pevonedistat	38-45	CD4 molecule	Homo sapiens	140-143
26676780-14	2015	The Nedd8 activation enzyme inhibitor MLN4924 blocks the activity of the host ubiquitin ligase that Vpu coopts to direct the degradation of CD4 and BST2.	pevonedistat	38-45	bone marrow stromal cell antigen 2	Homo sapiens	148-152
26807316-9	2015	Furthermore, we demonstrated that MLN4924 potentiated cisplatin-induced cytotoxicity in CC cells with activation of caspases.	pevonedistat	34-41	caspase 4	Homo sapiens	116-124
26807320-1	2015	MLN4924 is an experimental cancer drug known as inhibitor of NEDD8-activating enzyme (NAE).	pevonedistat	0-7	NEDD8 ubiquitin like modifier	Homo sapiens	61-66
27551465-0	2015	The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-alpha to activate apoptosis.	pevonedistat	18-30	tumor necrosis factor	Rattus norvegicus	57-66
27551465-5	2015	Through this approach, synergistic cytotoxicity between the investigational agent pevonedistat (MLN4924) and TNF-alpha was identified.	pevonedistat	82-94	tumor necrosis factor	Rattus norvegicus	109-118
27551465-11	2015	Interestingly, the combination treatment of pevonedistat and TNF-alpha also caused an accumulation of the p10 protease subunit of caspase-8 that was not observed with cytotoxic doses of TNF-alpha.	pevonedistat	44-56	caspase 8	Rattus norvegicus	130-139
25971362-0	2015	Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.	pevonedistat	79-86	microRNA 155	Homo sapiens	29-36
25971362-0	2015	Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.	pevonedistat	79-86	NEDD8 ubiquitin like modifier	Homo sapiens	45-50
25971362-0	2015	Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.	pevonedistat	88-100	microRNA 155	Homo sapiens	29-36
25971362-0	2015	Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.	pevonedistat	88-100	NEDD8 ubiquitin like modifier	Homo sapiens	45-50
26158513-2	2015	We recently reported that MLN4924 (pevonedistat), an investigational agent that inhibits the NEDD8-activating enzyme (NAE), abrogates stromal-mediated NF-kappaB pathway activity and CLL cell survival.	pevonedistat	35-47	NEDD8 ubiquitin like modifier	Homo sapiens	93-98
26003431-2	2015	SUMMARY ANSWER: Neddylation inhibition by a selective NEDD8-activating enzyme inhibitor, MLN4924, significantly impairs human endometrial stromal cell (HESC) proliferation and decidualization and facilitates cell senescence, via p21 accumulation.	pevonedistat	89-96	NEDD8 ubiquitin like modifier	Homo sapiens	54-59
26003431-2	2015	SUMMARY ANSWER: Neddylation inhibition by a selective NEDD8-activating enzyme inhibitor, MLN4924, significantly impairs human endometrial stromal cell (HESC) proliferation and decidualization and facilitates cell senescence, via p21 accumulation.	pevonedistat	89-96	H3 histone pseudogene 16	Homo sapiens	229-232
25797246-9	2015	Moreover, blockage of autophagy enhanced the efficacy of MLN4924 in an orthotopic model of human liver cancer, with induction of NOXA and apoptosis in tumor tissues.	pevonedistat	57-64	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	129-133
26021757-6	2015	The protein abundance of CLC-1 was notably enhanced in the presence of MLN4924, a specific inhibitor of cullin-RING E3 ligases.	pevonedistat	71-78	chloride voltage-gated channel 1	Homo sapiens	25-30
25742093-2	2015	Inhibition of neddylation pathway has emerged as a promising anticancer strategy, as evidenced by development of the NEDD8-activating enzyme (NAE) inhibitor MLN4924.	pevonedistat	157-164	NEDD8 ubiquitin like modifier	Homo sapiens	117-122
25253782-7	2014	We found that MLN4924, a selective inhibitor of NEDD8-activating enzyme (NAE), effectively inhibits cullin neddylation and attenuates CBS9106-induced CRM1 degradation in a time- and dose-dependent manner.	pevonedistat	14-21	NEDD8 ubiquitin like modifier	Homo sapiens	48-53
25253782-7	2014	We found that MLN4924, a selective inhibitor of NEDD8-activating enzyme (NAE), effectively inhibits cullin neddylation and attenuates CBS9106-induced CRM1 degradation in a time- and dose-dependent manner.	pevonedistat	14-21	exportin 1	Homo sapiens	150-154
24713927-0	2014	MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.	pevonedistat	0-7	AKT serine/threonine kinase 1	Homo sapiens	38-41
25229838-5	2014	In vitro treatment with MLN4924, a small-molecule NEDD8-activating enzyme inhibitor, led to a dose-dependent decrease of viability in both established and primary cholangiocarcinoma cell lines.	pevonedistat	24-31	NEDD8 ubiquitin like modifier	Homo sapiens	50-55
24672057-0	2014	Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways.	pevonedistat	34-41	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	0-5
24672057-0	2014	Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways.	pevonedistat	34-41	ataxia telangiectasia and Rad3 related	Mus musculus	102-105
24672057-0	2014	Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways.	pevonedistat	34-41	breast cancer 1, early onset	Mus musculus	107-112
24672057-0	2014	Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways.	pevonedistat	34-41	breast cancer 2, early onset	Mus musculus	113-118
24713927-0	2014	MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.	pevonedistat	0-7	mechanistic target of rapamycin kinase	Homo sapiens	46-50
24713927-0	2014	MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.	pevonedistat	0-7	DNA damage inducible transcript 4	Homo sapiens	81-86
24713927-6	2014	Combining MLN4924 with the proteasome inhibitor bortezomib induces synergistic apoptosis in MM cell lines which can overcome the prosurvival effects of growth factors such as interleukin-6 and insulin-like growth factor-1.	pevonedistat	10-17	interleukin 6	Homo sapiens	175-221
24691136-0	2014	Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells.	pevonedistat	77-84	ubiquitin like modifier activating enzyme 3	Homo sapiens	13-17
24691136-0	2014	Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells.	pevonedistat	77-84	NEDD8 ubiquitin like modifier	Homo sapiens	43-48
24634471-0	2014	The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-kappaB activation and induces apoptosis in chronic lymphocytic leukemia B cells.	pevonedistat	38-45	NEDD8 ubiquitin like modifier	Homo sapiens	4-9
24457957-7	2014	In addition to the proteasome inhibitor Bortezomib, we identified the neddylation inhibitor MLN4924 and the fatty acid synthase inhibitor Orlistat as potent inducers of NOXA protein expression leading to apoptosis in MCL.	pevonedistat	92-99	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	169-173
24430184-7	2014	Treatment with MLN4924, a small molecule inhibitor of CRL E3s, also inhibited the formation of KrasG12D-induced lung tumors through a similar mechanism involving inactivation of NF-kappaB and mTOR and accumulation of tumor suppressor substrates.	pevonedistat	15-22	interleukin 31 receptor A	Homo sapiens	54-57
24430184-7	2014	Treatment with MLN4924, a small molecule inhibitor of CRL E3s, also inhibited the formation of KrasG12D-induced lung tumors through a similar mechanism involving inactivation of NF-kappaB and mTOR and accumulation of tumor suppressor substrates.	pevonedistat	15-22	mechanistic target of rapamycin kinase	Homo sapiens	192-196
23939375-2	2013	In this investigation, we evaluated the preclinical activity of MLN4924, an investigational inhibitor of the NEDD8-activating enzyme, in ovarian cancer cells.	pevonedistat	64-71	NEDD8 ubiquitin like modifier	Homo sapiens	109-114
24245672-8	2013	Treatment with MLN4924, an adenosine sulfamate analog which hinders the NEDD8 activating enzyme NAE1, blocked neddylation of cullin4A (CUL4A).	pevonedistat	15-22	NEDD8 ubiquitin like modifier	Homo sapiens	72-77
24245672-8	2013	Treatment with MLN4924, an adenosine sulfamate analog which hinders the NEDD8 activating enzyme NAE1, blocked neddylation of cullin4A (CUL4A).	pevonedistat	15-22	NEDD8 activating enzyme E1 subunit 1	Homo sapiens	96-100
24245672-8	2013	Treatment with MLN4924, an adenosine sulfamate analog which hinders the NEDD8 activating enzyme NAE1, blocked neddylation of cullin4A (CUL4A).	pevonedistat	15-22	cullin 4A	Homo sapiens	125-133
24245672-8	2013	Treatment with MLN4924, an adenosine sulfamate analog which hinders the NEDD8 activating enzyme NAE1, blocked neddylation of cullin4A (CUL4A).	pevonedistat	15-22	cullin 4A	Homo sapiens	135-140
23597704-7	2013	To this end, we used the Nedd8 E1 inhibitor MLN4924, which blocks the activity of all Cullin E3 ligases.	pevonedistat	44-51	NEDD8 ubiquitin like modifier	Homo sapiens	25-30
23597704-7	2013	To this end, we used the Nedd8 E1 inhibitor MLN4924, which blocks the activity of all Cullin E3 ligases.	pevonedistat	44-51	CDK2 associated cullin domain 1	Homo sapiens	86-92
22874562-0	2012	Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells.	pevonedistat	89-96	NEDD8 ubiquitin like modifier	Homo sapiens	55-60
23100467-0	2013	Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.	pevonedistat	99-106	NEDD8 ubiquitin like modifier	Homo sapiens	65-70
23527154-3	2013	Here, we comparatively tested NFkappaB activity abrogation through TPCA-1 (an IKK2 inhibitor), BAY 11-7082 (an IKK inhibitor poorly selective for IKK1 and IKK2), and MLN4924 (an NEDD8 activating enzyme (NAE)-inhibitor), and analyzed their anti-MM activity.	pevonedistat	166-173	nuclear factor kappa B subunit 1	Homo sapiens	30-38
23267066-4	2013	These findings were recapitulated by treatment with MLN4924, an inhibitor of NEDD8-activating enzyme.	pevonedistat	52-59	neural precursor cell expressed, developmentally down-regulated gene 8	Mus musculus	77-82
22874562-4	2012	By blocking CUL neddylation, MLN4924 inactivates CRL and causes the accumulation of CRL substrates that trigger cell cycle arrest, senescence and/or apoptosis to suppress the growth of cancer cells in vitro and in vivo.	pevonedistat	29-36	interleukin 31 receptor A	Homo sapiens	49-52
22874562-4	2012	By blocking CUL neddylation, MLN4924 inactivates CRL and causes the accumulation of CRL substrates that trigger cell cycle arrest, senescence and/or apoptosis to suppress the growth of cancer cells in vitro and in vivo.	pevonedistat	29-36	interleukin 31 receptor A	Homo sapiens	84-87
22439935-0	2012	Treatment-emergent mutations in NAEbeta confer resistance to the NEDD8-activating enzyme inhibitor MLN4924.	pevonedistat	99-106	NEDD8 ubiquitin like modifier	Homo sapiens	65-70
22366459-10	2012	By contrast, when Cdt1 is overexpressed or is stabilised by the neddylation inhibitor MLN4924, re-replication can occur throughout S phase.	pevonedistat	86-93	chromatin licensing and DNA replication factor 1	Homo sapiens	18-22
22439935-1	2012	MLN4924 is an investigational small-molecule inhibitor of NEDD8-activating enzyme (NAE) in clinical trials for the treatment of cancer.	pevonedistat	0-7	NEDD8 ubiquitin like modifier	Homo sapiens	58-63
21677879-0	2011	Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression.	pevonedistat	59-66	H3 histone pseudogene 16	Homo sapiens	13-16
21914854-0	2011	The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells.	pevonedistat	39-46	NEDD8 ubiquitin like modifier	Homo sapiens	4-9
21914854-0	2011	The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells.	pevonedistat	39-46	TNF superfamily member 10	Homo sapiens	64-69
21914854-0	2011	The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells.	pevonedistat	39-46	CASP8 and FADD like apoptosis regulator	Homo sapiens	112-118
21417215-0	2011	Stereoselective synthesis of MLN4924, an inhibitor of NEDD8-activating enzyme.	pevonedistat	29-36	NEDD8 ubiquitin like modifier	Homo sapiens	54-59
21145461-4	2010	Contrary to expectations, acute CRL inhibition with MLN4924, an inhibitor of the NEDD8-activating enzyme, does not result in a global reorganization of the CRL network.	pevonedistat	52-59	NEDD8 ubiquitin like modifier	Homo sapiens	81-86
20603103-4	2010	In this study, we utilize dominant-negative Ubc12 (dnUbc12) and the Nedd8 E1 inhibitor MLN4924 to inhibit cellular neddylation.	pevonedistat	87-94	NEDD8 ubiquitin like modifier	Homo sapiens	68-73
20129059-0	2010	Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.	pevonedistat	99-106	NEDD8 ubiquitin like modifier	Homo sapiens	80-85
20129059-0	2010	Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.	pevonedistat	99-106	NEDD8 ubiquitin like modifier	Homo sapiens	115-120